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Abstract
Aging and cancer are inexorably linked. As the average life expectancy increases, so does the incidence of
cancer. Senescence, the irreversible growth arrest that occurs in response to prolonged cellular stress, is one
cellular state that affects both cancer and aging. Senescence acts as an anti-tumor mechanism that protects
cells from undergoing oncogenic transformation, but senescent cells also secrete factors as part of the
senescence-associated secretory phenotype (SASP) that can affect their environment in both positive and
negative ways. The SASP is known to be regulated by interleukin (IL)-1α, which initiates a feed-forward
mechanism involving NF-κB and C/EBPβ. Non-senescent cells also secrete factors in response to different
types of stress. Using an RNA microarray to analyze the secreted factors upregulated by cells with high levels
of DNA damage, we identified two interleukin IL-10 family members, IL-19 and IL-24, that were upregulated
with DNA damage. Using an in vitro approach, we validated the upregulation of these factors in the context of
different types of damage. IL-19 was upregulated in response to ionizing radiation (IR) in multiple cell lines,
reaching a peak in mRNA levels 3-4 days after IR treatment. This induction was independent of classical SASP
signaling, including IL-1 and ataxia telangiectasia mutated (ATM). Instead, IL-19 induction was dependent
on reactive oxygen species (ROS) and c-Jun N-terminal kinase ( JNK) signaling. Importantly, we showed that
known SASP factors, including IL-1, IL-6, and IL-8, are regulated by IL-19 induction. IL-24, on the other
hand, is induced in response to S-phase-specific DNA damage, in a temporally restricted manner; in multiple
cell lines examined, maximal IL-24 mRNA induction occurred within 24 hours of stress treatment, and
quickly returned to baseline levels. Like IL-19 induction, IL-24 induction was independent of DNA damage
response proteins such as ATM, but unlike IL-19, was dependent on p38MAPK activation. We also found
that in a mouse pancreatic intraepithelial neoplasia cell line, apoptosis caused by fork collapse was attributable
to IL-24 induction, as IL-24 shRNAs prevented cell death induced by ATR inhibitor plus aphidicolin. These
studies demonstrate an important role for IL-19 and IL-24 in the regulation and effects of DNA damage-
induced cytokine signaling, and open up the possibility of manipulating these factors in the treatment of
cancer and age-related diseases.
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ABSTRACT 
IL-10 FAMILY MEMBERS AS NOVEL RESPONDERS TO CELLULAR DAMAGE 
Sara H. Small 
Eric J. Brown 
 
Aging and cancer are inexorably linked. As the average life expectancy increases, so does 
the incidence of cancer. Senescence, the irreversible growth arrest that occurs in response 
to prolonged cellular stress, is one cellular state that affects both cancer and aging. 
Senescence acts as an anti-tumor mechanism that protects cells from undergoing 
oncogenic transformation, but senescent cells also secrete factors as part of the 
senescence-associated secretory phenotype (SASP) that can affect their environment in 
both positive and negative ways. The SASP is known to be regulated by interleukin (IL)-
1α, which initiates a feed-forward mechanism involving NF-κB and C/EBPβ. Non-
senescent cells also secrete factors in response to different types of stress. Using an RNA 
microarray to analyze the secreted factors upregulated by cells with high levels of DNA 
damage, we identified two interleukin IL-10 family members, IL-19 and IL-24, that were 
upregulated with DNA damage. Using an in vitro approach, we validated the 
upregulation of these factors in the context of different types of damage. IL-19 was 
upregulated in response to ionizing radiation (IR) in multiple cell lines, reaching a peak 
in mRNA levels 3-4 days after IR treatment. This induction was independent of classical 
SASP signaling, including IL-1 and ataxia telangiectasia mutated (ATM). Instead, IL-19 
induction was dependent on reactive oxygen species (ROS) and c-Jun N-terminal kinase 
(JNK) signaling. Importantly, we showed that known SASP factors, including IL-1, IL-6, 
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and IL-8, are regulated by IL-19 induction. IL-24, on the other hand, is induced in 
response to S-phase-specific DNA damage, in a temporally restricted manner; in multiple 
cell lines examined, maximal IL-24 mRNA induction occurred within 24 hours of stress 
treatment, and quickly returned to baseline levels. Like IL-19 induction, IL-24 induction 
was independent of DNA damage response proteins such as ATM, but unlike IL-19, was 
dependent on p38MAPK activation. We also found that in a mouse pancreatic 
intraepithelial neoplasia cell line, apoptosis caused by fork collapse was attributable to 
IL-24 induction, as IL-24 shRNAs prevented cell death induced by ATR inhibitor plus 
aphidicolin. These studies demonstrate an important role for IL-19 and IL-24 in the 
regulation and effects of DNA damage-induced cytokine signaling, and open up the 
possibility of manipulating these factors in the treatment of cancer and age-related 
diseases. 
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Introduction 
As the average human lifespan continues to increase, we are faced with an 
increased incidence of aging-related diseases, including cancer. While some organisms 
continuously grow and gain strength during their lives, such as lobsters, humans 
experience a general decline in health with age. The existence of negative symptoms of 
aging is not surprising, as there is no evolutionary selection after reproductive age has 
passed. In fact, certain processes that that are putatively beneficial at a younger age 
(before and during reproductive age) may become detrimental at an older age, after 
reproductive fitness has declined. This concept is called antagonistic pleiotropy, and may 
explain many features of aging. For example, the process of senescence acts as a barrier 
against tumorigenesis at an early age, but may eventually result in inflammatory 
phenotypes associated with aging, as well as increased risks for cancer.  
Human progeroid syndromes provide some insight into mechanisms of aging. For 
example, multiple premature aging syndromes are caused by defects in DNA damage 
repair pathways that quickly lead to accumulations of DNA damage, such as ataxia 
telangiectasia, Werner syndrome, Bloom’s syndrome, and Hutchinson-Gilford syndrome. 
Discovering the defects responsible for these diseases has demonstrated that DNA 
damage, and the response to DNA damage, play significant roles in aging, on top of their 
well-recognized roles in cancer. Other important players in aging and cancer 
development discussed below include reactive oxygen species (ROS), senescence, and 
the senescence-associated secretory phenotype (SASP). Not surprisingly, there is 
substantial overlap in the processes of aging and cancer, as well as the mechanisms 
underlying the development and progression of each.  
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Mechanisms of Aging 
 Aging can generally be conceptualized as the progressive dysfunction of tissue 
homeostasis, with eventual death of the organism. Many diseases are associated with 
aging, including cancer and bone marrow failure, which fall on two ends of the 
dysfunctional aging spectrum. Cancer represents an overactive type of tissue 
homeostasis, and bone marrow failure represents a breakdown of tissue homeostasis. No 
matter the pace of age-related decline, eventually all organisms will succumb to the 
negative effects of aging. While the process of aging, on some level, has been observed in 
all known multicellular organisms, the mechanisms of age-induced tissue dysfunction are 
still not well understood. In fact, there are multiple widely-studied potential mechanisms 
of aging.  
One mechanism of aging that is commonly studied stems from the free radical 
theory of aging1. This theory postulates that aging is caused by endogenous oxidant 
radicals, which cause an accumulation of DNA damage over time. This theory originally 
presented a link between metabolic rate and aging, as mitochondria produce the majority 
of endogenous free radicals. It is now more widely thought that it is specifically reactive 
oxygen species (ROS) production that determines longevity, rather than metabolic rate in 
itself. Indeed, there is an increase of ROS in aged cells compared to young cells2. 
Additionally, the longest-living non-colonial animal, the ocean quahog, exhibits an 
increased resistance to oxidative stress and ROS-induced cell death, as compared to the 
northern quahog, a taxonomically-related clam with similar physiology but significantly 
shorter life-span3. 
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Another important factor in aging is stem cells. Stem cells are required for 
generating new functional daughter cells on an as-needed basis throughout an organism’s 
life. When new daughter cells are not required, stem cells mainly stay in a quiescent state. 
Stem cells are important for tissue homeostasis in both rapidly proliferating tissues (such 
as bone marrow or skin), as well as tissues with less rapid turnover rates (such as the 
brain). To date, hematopoietic stem cells (HSCs) are the best characterized stem cells, as 
distinct immunophenotyping allows for successful isolation of different cell populations. 
The study of HSCs has shown that stem cells generally lose functionality with age. 
Clinical evidence of this functional decline in humans includes the increased incidence in 
anemia and bone marrow failure with age, decrease in functional immunity with age4, 
and inverse correlation of increased age of bone marrow donor with survival of bone 
marrow recipient5. These phenotypes are due to the decline in replicative potential of 
HSCs with age, as well as a decreased functional ability of each stem cell with age. For 
example, HSCs from older organisms have defects in differentiation, resulting in a 
significant skewing towards myeloid lineages6, and defects in homing and mobilization7. 
There is a wealth of evidence showing that DNA damage in stem cells leads to 
aging. For example, stem cells accumulate DNA damage with age8. Premature 
differentiation of stem cells can be induced by DNA damage, resulting in decreased 
plasticity of tissues, such as the loss of melanocyte stem cells with age that leads to 
premature hair graying9. Additionally, our laboratory has shown that deletion of the 
replication-essential gene ATR in mice, causing high levels of DNA damage in 
replicating cells, leads to increased pressure on and turnover of the remaining stem cells, 
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resulting in premature aging10. Thus, DNA damage that causes exhaustion of the 
replicative potential of tissue stem cells results in aging.  
The stem cell niche may also contribute to the aging of stem cells in a non-cell 
autonomous manner. One example of the importance of non-stem-cell autonomous 
factors in aging is demonstrated in mouse models of parabiosis, where the circulatory 
systems of two mice are connected. This connection allows for blood and circulating 
factors to transfer freely between mice. In a heterochronic parabiosis model, where a 
young mouse is surgically linked to an older mouse, it was shown that rejuvenation of the 
older mouse’s tissues took place, as well as decline or aging of the younger mouse’s 
tissues11. Since stem cells are not known to circulate at high frequency through the blood, 
this result suggests that there are other factors in the blood that affect stem cells and 
tissue function in a non-cell autonomous manner.  
DNA damage can also affect aging via the process of cellular senescence. 
Replicative senescence, or Hayflick’s limit, was initially described as an in vitro 
phenomenon by Leonard Hayflick in 196512. It has since been demonstrated to occur in 
vivo as well. Senescence is the essentially irreversible growth arrest undergone by cells in 
response to a variety of stresses, including telomere dysfunction, oncogenic stress, 
oxidative stress, and ionizing radiation. Each of these stresses results in activation of a 
DNA damage response (DDR) and cell cycle arrest, as well as some characteristic 
features of senescence, such as an increase in senescence-associated β-galactosidase 
activity, p16INK4a levels, p21 levels, and formation of senescence-associated 
heterochromatic foci (SAHFs). Of note, there are a few stimuli that cause senescence in 
the absence of a significant DDR, such as the loss of the tumor suppressor Pten13, or 
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ectopic expression of p16INK4a14. Senescence is a conserved process that has recently 
been shown to occur in non-replicating cells (post-mitotic neurons15) as well as 
replicating cells. 
As opposed to cells that undergo apoptosis in response to DNA damage, however, 
senescent cells remain metabolically active, and unless cleared by the immune system, 
are capable of persisting in tissues for an indefinite amount of time16. Senescent cells 
have been shown to accumulate with age16, and it has been suggested that this 
accumulation of senescent cells is responsible for tissue dysfunction associated with 
aging. This purported connection between senescence and aging, however, begs the 
question of why senescence would have evolved. One compelling explanation is the 
concept of antagonistic pleiotropy17, which stipulates that some biological processes are 
beneficial to an organism early in its life and detrimental later in its life. The most 
important benefit of senescence early in life, besides a potential role in wound healing 
and embryonic development, is that senescent cells represent a potent anti-tumor 
mechanism18. That is to say, when cells undergo sufficient damage such that they may 
otherwise continue replicating and eventually form a tumor, senescence causes cell-cycle 
arrest, and whether subsequently cleared by the immune system or not, the damaged cells 
will no longer continue replicating and accumulating DNA damage that could lead to 
tumorigenesis. It has also been shown that senescence is important for wound healing19 
and embryonic development20,21. Thus, some of the normal functions of senescence 
include stimulation of inflammation and tissue remodeling.  
 
DDR and Oncogene Regulation of Senescence 
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One of the first papers postulating senescence as a DNA damage-induced barrier 
to tumorigenesis compared the DNA damage response (DDR) in cells that were normal, 
pre-malignant, or at different levels of malignancy22. For example, they showed 
activation of Chk2 and ATM in bladder tumors, which generally preceded the 
development of p53 mutations22. This DDR activation was also present in other early 
human tumors, such as colorectal adenomas and lung hyperplasia, suggesting that 
constitutive DDR activation occurs at pre-invasive stages of many human cancers22.  
There have been many publications describing the role of the DDR in oncogene-
induced senescence (OIS). One of the first papers showing a causal link between DDR 
activation and OIS used human fibroblast cells that expressed oncogenic HRAS 
(HRASV12)23. They observed that cells undergoing OIS, but not control cells, had many 
DNA damage foci with active ATM, NBS1, and ATRIP. OIS was then rescued by 
knockdown of CHK2, ATM, or p5323. They also observed that the introduction of 
HRASV12 into cells caused a proliferative burst before senescence, which was 
accompanied by an increased number of active replication forks. Therefore, they 
concluded that oncogene expression leads to hyper-replication which creates the DDR 
leading to senescence, and that the DDR was essential for preventing these cells from 
undergoing oncogenic transformation. Another group also showed that cells that 
underwent senescence in response to oncogenic HRAS (RASG12V) had sustained 
activation of the DDR pathway, as seen by γH2AX staining, 53BP1 foci, and 
phosphorylated ATM (Ser 1981), and that the cells were able to bypass OIS when treated 
with siRNAs against ATM, despite a persistent activation of the DDR24.  
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Senescence can also be triggered by the loss of tumor suppressors. For example, 
loss of the tumor suppressor PTEN triggers senescence in primary mouse embryonic 
fibroblasts, and senescence protects PTEN-deficient prostates from tumorigenesis in 
mice25. Loss of von Hippel-Lindau tumor suppressor gene (VHL) also causes senescence 
in vitro and in vivo26. The mechanism of tumor suppressor loss-induced senescence is less 
well characterized than that of OIS, though it likely works through similar pathways. 
Most types of senescence-inducing stimuli cause DNA damage. Not surprisingly, 
accumulation of DNA damage is associated with aging and the development of multiple 
age-related human diseases including heart disease and type 2 diabetes27. Recently, it was 
shown that DNA DSBs specifically induce features of aging in mouse liver28. Mice were 
infected with an adenovirus with doxycyline-inducible expression of the SacI restriction 
enzyme. Young mice with induced SacI expression displayed certain features of normal 
aging, though not all expected features. Thus, there is much evidence that DNA damage 
is sufficient to cause age-related pathologies and lies at the center of most theories about 
the mechanism of aging, whether through the accumulation of damage from free radicals, 
decline in stem cell function, or increase in senescent cells.  
 
The Radiation Bystander Response and the SASP  
While DNA damage is known to cause cell-intrinsic effects, such as premature 
differentiation of stem cells or cellular senescence, it can also result in cell-extrinsic 
effects on the surrounding tissue milieu. Many senescent cells develop a senescence-
associated secretory phenotype (SASP), which promotes inflammation and cell growth in 
surrounding cells. The SASP is a cellular response to high levels of persistent DNA 
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damage. Despite its name, it is capable of occurring in the absence of senescence. For 
example, cells that are incapable of undergoing senescence-associated growth arrest 
because of deleted p16INK4a14 and p21 are still capable of mounting a SASP. On the 
other hand, cells that ectopically express p16INK4a undergo senescence without 
mounting a SASP, suggesting that it is the stimulus that causes damage or senescence 
rather than the outcome of senescence, per se, which results in a SASP14. The SASP 
consists of a large panel of inflammatory proteins, proteases, and growth factors. Thus 
the SASP has a wide range of effects, both cell-autonomous and non-cell autonomous. 
For example, interleukin (IL)-6 helps reinforce senescence-associated cell cycle arrest in 
an autocrine fashion, but also stimulates proliferation and survival in surrounding cells in 
a paracrine manner.  
The SASP was first described in the context of oncogenic RAS and p53; more 
specifically, the SASP was found to be intensified by either expression of oncogenic RAS 
or loss of p53, again connecting senescence and the SASP to the DDR. It was also noted, 
however, that the timing of SASP induction was much slower than the DDR response, 
suggesting that the SASP is not simply part of the classic DDR29. In order to identify the 
factors involved in the SASP, conditioned media from non-senescent and senescent cells 
were collected and analyzed using antibody arrays that were capable of detecting 120 
different proteins. Of note, this initial antibody array only consisted of proteins with 
known roles in intercellular signaling, and thus was likely incomplete. Nonetheless, the 
array results showed a significant overlap of SASPs mounted by different cell types (such 
as fibroblasts and epithelial cells) and in response to different senescence-inducing 
stimuli (such as replicative senescence and oncogene-induced senescence), suggesting 
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that the SASP is a conserved response. Lastly, they showed that the SASP was able to 
induce an epithelial-to-mesenchymal transition in non-aggressive breast cancer lines, 
suggesting that the SASP likely has many important effects in vivo, and that senescent 
cells are not simply an effective tumor-suppressive mechanism29. The same group later 
showed that initiation and maintenance of the SASP requires a persistent DNA damage 
signal30, suggesting that transient DDRs are not sufficient to cause a SASP.   
One of the earliest papers establishing a connection between OIS and 
inflammatory factors focused on IL-6 and IL-831. This group performed a genome-wide 
expression microarray analysis to compare cells that underwent OIS (via BRAFE600 
expression) with cells that bypassed OIS. They found a significant difference in the levels 
of cytokines and chemokines, with more upregulation in the OIS cells than the controls. 
IL-6 and IL-8 were identified as OIS-activated cytokines, and induction of both IL-6 and 
IL-8 was found to be dependent on the transcription factor C/EBPβ. Importantly, 
upregulation of both IL-6 and IL-8 was required for efficient OIS.  
IL-6 and IL-8 are regulated by IL-1α, which is considered the master regulator of 
the SASP32. Once persistent DNA damage signaling causes a cell to undergo senescence, 
IL-1α is upregulated, which then signals through the IL-1 receptor, activating myeloid 
differentiation primary-response protein 88 (MyD88) and IRAKs. This causes activation 
of transcription factors such as NF-κB and C/EBPβ, resulting in further upregulation of 
IL-1α, as well as transcription of downstream SASP factors, such as IL-6 and IL-8. 
Mammalian target of rapamycin (mTOR) activity is required for senescence-induced IL-
1α upregulation, which occurs mostly post-transcriptionally; inhibiting the mTOR 
pathway by treating cells with rapamycin suppresses translation of the membrane-bound 
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form of IL-1α, leading to suppression of many downstream SASP factors33. Importantly, 
IL-1α is synthesized as a precursor protein and requires the Ca2+-activated protease 
calpain for processing to its mature form34, though it is also active in its immature form35. 
It has been shown that this process is mediated by senescence-associated oxidative 
stress36. Since oxidative stress itself can induce senescence and appears to be a common 
factor in many different types of senescence (including OIS and replicative senescence)37, 
it is not surprising that it also plays an important role in SASP induction. 
Other important players in SASP regulation include ATM, p38MAPK, and ROS. 
p38MAPK was shown to be activated by many different senescence-inducing stimuli 
(such as IR), and inhibition of p38MAPK prevented much of the SASP response, 
including secretion of IL-6 and IL-8, by decreasing activation of the NF-κB pathway38. 
Interestingly, p38MAPK inhibition does not prevent secretion of some SASP factors, 
such as MMP1 and MMP338. Infecting cells with a constitutively active mutant of a 
p38MAPK regulating protein, rendering p38MAPK constitutively active, caused 
senescence and induced many SASP factors, including IL-6, independent of a DDR (i.e. 
without activating ATM, CHK2, or p53). A p38MAPK inhibitor was able to rescue the 
accelerated aging in Werner Syndrome cells39. Thus, while the DDR is important for 
inducing a SASP in most contexts, there are some contexts in which it is not essential, 
likely when downstream targets are more directly activated. 
One such target that lies downstream of the DDR and p38MAPK is NF-κB. It has 
been shown that inhibition of NF-κB is sufficient to prevent upregulation of certain SASP 
factors in senescent cells, including IL-6 and IL-840,41. Besides its role in promoting 
transcription of SASP genes, NF-κB appears to be involved in aging in other ways. For 
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example, based on gene expression patterns, NF-κB has been identified as the 
transcription factor that is most highly associated with mammalian aging42. Further 
evidence of NF-κB’s role in aging and the SASP comes from mouse models, where 
heterozygous deletion of the NF-κB subunit p65 was sufficient to delay the usual 
pathologies seen in XFE progeroid mice, such as neurodegeneration and osteoporosis, 
which coincided with a decrease in the number of senescent cells and ROS43. These mice 
have mutations in XPF, which encodes a DNA repair endonuclease, leading to 
accelerated aging in virtually all tissues. Similar phenotypes were seen in mice treated 
with a pharmacological inhibitor of the NF-κB activating kinase IKK43. NF-κB 
inactivation in a mouse model of hepatocellular carcinoma allowed tumor cells to bypass 
senescence40, suggesting that NF-κB may have a role in senescence induction as well as 
the SASP. ROS can also stimulate the NF-κB pathway44. Corticosteroids are able to 
suppress certain components of the SASP, such as IL-6 and IL-8, at least in part by 
blocking the IL-1α/NF-κB positive feedback loop that normally initiates SASP factor 
expression and secretion33. Metformin also prevented induction of the SASP by blocking 
NF-κB activation, which may also explain metformin’s unanticipated cancer prevention 
activity45. 
Another important aspect of the SASP is that it is able to cause a phenomenon 
known as paracrine senescence, whereby a senescent cell can propagate senescence via 
the SASP to nearby cells. Paracrine senescence is regulated by IL-1 processing by the 
inflammasome46. Paracrine senescence might be considered to be a form of the senescent 
cell bystander effect, in which senescent cells cause DNA damage to nearby cells via gap 
junctions and ROS47, or by secreted factors such as the SASP48. 
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Even before the senescent cell bystander effect was described, a similar 
phenomenon was described in cells that had been exposed to ionizing radiation (IR). IR 
has many effects on cells: it creates a secondary electron that is absorbed by DNA, RNA 
or proteins, and it also creates free radicals which go on to cause more damage49. For 
example, IR causes significant numbers of double strand breaks in DNA. Additionally, 
IR can affect other, non-IR exposed cells, via the radiation-induced bystander effect50. 
This effect describes the phenomenon where radiation of one cell affects surrounding 
cells. The mechanism of radiation-induced bystander effect is still not completely 
understood, though it has been shown to require gap junctions, MAPK signaling, and 
cyclooxygenase-2, among others51. Of note, IR can also induce cellular senescence. 
Ionizing radiation also causes substantial activation of multiple mitogen-activated protein 
kinase (MAPK) pathways components, such as ERK and JNK52. H-Ras-induced 
senescence also activates the MEK/MAPK/ERK and p38MAPK pathways53. Thus, there 
is potential for overlap between the radiation bystander effect and the senescence 
bystander effect. 
 
Oxidative Stress and Aging 
There have been multiple reports suggesting that oncogenes induce senescence 
via increases in cellular levels of oxidative stress. For example, when mutant RAS (V12) 
is expressed in cells, it causes an increase in ROS within a week of infection, which 
precedes the development of senescence markers54. The senescence-associated growth 
arrest associated with infection with mutant RAS was rescued by incubating cells in 1-
3% oxygen instead of 20% oxygen, the latter environment causing more oxidative stress. 
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This growth arrest was also rescued by the addition of an ROS (peroxide) scavenger. 
Oxidative stress can also cause senescence without oncogene expression; hydrogen 
peroxide is sufficient to cause a senescence-like growth arrest in human fibroblast 
cells55,56. 
Notably, ROS have also been proposed to be important for signaling proliferation, 
which seems at odds with its role in growth arrest. However, it has more recently been 
shown that ROS cause senescence by driving a hyperproliferative phase with aberrant 
DNA replication, which ultimately results in a DDR and senescence-associated growth 
arrest57. Interestingly, the OIS only occurred if cells were proliferating at the time of 
oncogenic RAS expression, despite the fact that ROS increased in both proliferating and 
quiescent cells. Therefore, ROS appear to only cause senescence via this 
hyperproliferative phase. C-Myc can also cause an elevation in ROS levels, resulting in 
DNA damage and senescence, rescuable by the addition of ROS scavengers58. BRAFE600, 
among other oncogenes59, has also been shown to be capable of inducing OIS.  
There have been many different mechanisms described for ROS induction by 
oncogenes. For example, the production of ROS by K-RASV12 expression requires Ras-
related C3 botulinum toxin substrate 1 (Rac1) and NADPH oxidase (Nox4)57,60. The RAS 
pathway has also been shown to cause ROS and subsequent senescence via 5-
Lipoxygenase (5LO) activation61 and decreased expression of sestrin genes SESN1 and 
SESN3 via modulation of the stress-responsive transcription factor HSF1 in a cell-type-
dependent manner62.  Expressing a constitutively active allele of AKT, causing inhibition 
of FOXO3a and therefore an increase of ROS, also results in ROS-dependent 
senescence63. 
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ROS may also play a role in replicative senescence. Cells that have undergone 
replicative senescence have higher levels of ROS, and human fibroblasts cannot be 
immortalized by telomerase when grown at high levels (20%) of oxygen, suggesting that 
DNA damage caused by ROS may be involved in replicative senescence as well as OIS. 
Additionally, treatment of cells with antioxidants delays replicative senescence56, and 
oxidative stress can directly cause damage to telomeres and accelerate their shortening64. 
Taken together, these results demonstrate an essential involvement of ROS in multiple 
contexts of senescence. 
  
Effects of Senescence and Secreted Factors on Cancer  
The greatest risk factor for developing cancer is aging, suggesting an inexorable 
link between the two. As described above, senescence is a powerful cell autonomous 
anti-tumor mechanism. In fact, restoring p53 in p53-deficient liver carcinomas in mice 
causes regression of disease via senescence and SASP-induced recruitment of the 
immune system for clearance65. If senescent cells develop a SASP, however, senescence 
can contribute to tumorigenesis in a paracrine manner66. p16INK4a, a common marker of 
senescent cells, increased exponentially with age in a luciferase knock-in mouse model67. 
Expression of p16INK4a was seen in all fourteen tumor models that this group tested, 
both in the emerging neoplasm and the surrounding stromal cells67. It is now recognized 
that inflammation is a hallmark of aging and an “enabling characteristic” in cancer68.  
Additionally, senescent cells were recently shown to have a similar epigenetic landscape 
to cancer cells69. 
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The SASP contains pro-survival and pro-proliferation factors, such as IL-670, as 
well as chemokines that recruit in inflammatory cells. Certain components of the SASP, 
namely IL-6, IL-8, and growth-related oncogene (GROα) can also stimulate EMT71, 
leading to metastasis. Senescent fibroblasts are able to cause premalignant mammary 
epithelial cells to become invasive and malignant72. Senescent fibroblasts are also able to 
promote growth of human xenograft tumors by secreting matrix metalloproteinases 
(MMPs), which are components of the SASP73. The same MMPs, however, are important 
for wound healing19 and limiting fibrosis in response to tissue injury74. This function of 
MMPs and other SASP factors in a physiological context demonstrates a connection 
between the normal role of senescent cells as signal amplifiers and SASP factors. Thus, 
the accumulation of senescent cells with age likely contributes to both aging and cancer.  
Another connection between senescence and cancer is therapy-induced 
senescence; most cancer therapies cause massive DNA damage, leading to either 
apoptosis or senescence75. The level of therapy-induced senescence may even represent a 
positive prognostic biomarker in cancer treatment. However, the reverse may be true in 
certain cancers. For example, in a mouse model of breast cancer, tumors harboring cells 
that were able to undergo senescence (wild-type p53) fared worse than tumors with 
mutant p53; the former tumor cells persisted and may have contributed to relapse, 
whereas the latter  continued to proliferate at first but then underwent mitotic catastrophe 
and apoptosis76. The tumors with senescent cells not only demonstrated less apoptosis, 
but also the senescent cells expressed inflammatory cytokines that may have induced 
proliferation in neighboring, non-senescent cells76.   
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IL-19 and IL-24 
One family of cytokines that has not previously been described in the context of 
senescence and the SASP is the IL-10 family. The IL-20 family of cytokines is a 
subfamily within the larger IL-10 family of cytokines, and is comprised of IL-19, IL-20, 
IL-22, IL-24, and IL-26. Both IL-19 and IL-24 are located close to the IL-10 gene on 
Chromosome 178,77. While IL-19 and IL-24 seem to have overlapping functions in some 
contexts, there are also several differences between the two cytokines. 
IL-19 was first cloned in the year 200078. IL-19 signals through IL-20 receptor 
type one, which is composed of the IL-20 receptor α chain and the IL-20 receptor β 
chain79. Activation of the IL-20 type one receptor results in downstream signaling of the 
Janus Kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. IL-
19 is expressed in activated monocytes, stromal cell lines derived from pancreatic, colon, 
prostate, and breast tissues80, keratinocytes81, fibroblasts82, and airway epithelial cells83.  
IL-24 was first identified as a tumor suppressor in melanocytes and named 
melanoma differentiation associated factor 7 (MDA-7) because it was upregulated in 
human melanoma cells that were forced to terminally differentiate by drug treatment84. 
IL-24 signals through the IL-20 type one receptor, as well as through the IL-20 type two 
receptor, which contains the IL-20 receptor β chain as well as the IL-22 receptor α1 
chain79. Like IL-19, IL-24-induced activation of the IL-20 type one receptor results in 
downstream signaling of the Janus Kinase (JAK)/signal transducer and activator of 
transcription (STAT) pathway. Unlike IL-19, however, IL-24 can also activate the 
JAK/STAT pathway by binding to the IL-20 type two receptor. IL-24 is expressed in 
melanocytes85, keratinocytes86, Th2 cells87, macrophages and monocytes88,89, stromal cell 
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lines derived from skin, colon, and breast tissues80, endothelial cells90, and colonic 
subepithelial myofibroblasts91. 
IL-19 and IL-24 are expressed at high levels in human psoriasis92,93, and their 
receptors are expressed in primary human keratinocytes94. More specifically, IL-19 
expression is seen in basal and suprabasal keratinocytes and may be pathologic in 
psoriasis, as it upregulates keratinocyte growth factor transcripts in T cells, which could 
explain the pathologic hyperproliferation of keratinocytes seen in psoriatic plaques95. 
Interestingly, treating patients with topical calcipotriol or oral cyclosporine decreased IL-
19 mRNA levels and resulted in histopathologic improvement of psoriasis93. Both IL-19 
and IL-24 are able to stimulate epidermal hyperplasia and proliferation of normal human 
epidermal keratinocytes (NHEK) in monolayer cultures, and to induce phosphorylation 
and nuclear localization of Stat394. Transgenic mice that overexpress IL-24 under the 
keratin 5 promoter exhibit marked epidermal hyperplasia and macrophages infiltrating 
the skin96, similarly to the pathology seen in psoriasis. 
In addition to psoriasis, IL-19 and IL-24 are implicated in other inflammatory 
conditions. Serum levels of IL-19 and IL-24 are elevated in patients with active 
inflammatory bowel disease (IBD) as compared to patients with inactive IBD or healthy 
controls97,91. However, IL-19-deficient mice have an increased sensitivity to dextran 
sodium sulfate (DSS)-induced colitis, suggesting that IL-19 may protect against mucosal 
inflammation98. Rheumatoid arthritis (RA) is characterized by an inflammatory process 
in the joints involving cytokines such as IL-1, IL-6, IL-8, and MCP-190. IL-19 is thought 
to have a pathogenic role in RA because it can increase the proliferation of synovial cells 
and induce their production of IL-6, IL-8 and MCP199,100. Additionally, blocking IL-19 
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was shown to improve experimentally-induced autoimmune arthritis82. IL-24 is present at 
higher levels in synovial fluid of patients with RA than in patients with osteoarthritis 
(OA) or healthy volunteers90. Lastly, elevated IL-19 levels are found in the airway 
epithelia of asthmatic patients77, and IL-19 has been implicated in the pathogenesis of 
endotoxic shock, as it is able to increase neutrophil chemotaxis and induce production of 
IL-1β, IL-6, IL-8, CCL5, and CXCL9 in lung epithelial cells77. 
IL-19 is important for wound healing. It causes fibroblasts to increase expression 
and secretion of keratinocyte growth factor, resulting in wound healing101. Additionally, 
IL-19 increases angiogenesis in a reperfusion mouse model102. Both IL-19 and IL-24 are 
induced in wounded skin in mice or humans97,103 and induce antimicrobial responses in 
epithelial cells by promoting production of antimicrobial peptides such as psoriasin and 
β-defensins94.  They also help strengthen the barrier function of the epithelium, partially 
by stimulating epithelial cells to proliferate and differentiate, and partly by inducing 
genes important for wound healing94. IL-19 is also induced in injured human arteries and 
prevents vascular smooth muscle cell hyperplasia104 by reducing stability of proliferative 
and inflammatory transcripts, such as IL-1β, IL-8, and COX2105. IL-19 and IL-24 are 
induced by Staphylococcus aureus106. Thus, although they are involved in multiple 
inflammatory disorders, IL-19 and IL-24 are also important for maintaining basic 
defenses and epithelial integrity. In fact, IL-19 seems to have an anti-inflammatory effect 
in some cases. As mentioned above, IL-19 knockout mice have an increased sensitivity to 
dextran sodium sulfate-induced colitis, which is accompanied by an accumulation of 
macrophages and increased production of various cytokines98.  
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There is some evidence to suggest that IL-19 may have a role in some cancers. 
First, multiple types of tumor cells stain positively for IL-19 protein, especially squamous 
cell carcinomas (from the tongue, esophagus, lung, and skin)107. Additionally, high IL-19 
expression in human invasive ductal carcinoma is associated with advanced tumor stage, 
increased rate of metastasis, and worse survival108. IL-19 was also able to induce 
expression of IL-1β, IL-6, TGF-β, MMP2, MMP9, and CXCR4, and promote breast 
cancer cell proliferation and migration in vitro108. In esophageal cancer, high IL-19 
expression is associated with advanced tumor stage and metastasis109. 
IL-24 was originally discovered in the context of cancer. Specifically, it was 
found to be downregulated in melanoma cells as compared to non-transformed 
melanocytes84, and its expression was re-activated when melanoma cells were forced to 
undergo terminal differentiation84. IL-24 expression during terminal differentiation in 
melanoma cells is regulated primarily at the post-transcriptional level110: the 3’ 
untranslated region (UTR) of IL-24 mRNA contains AU-rich elements (AREs) which 
cause destabilization of mRNA. In some contexts, IL-24 induction is dependent on 
p38MAPK-mediated stabilization of IL-24 mRNA111. However, there is some evidence 
to suggest that the AP-1 and C/EBP families of transcription factors also play a role in 
activation of IL-24 transcription112.  
IL-24 has the ability to cause apoptosis in transformed cells but not non-
transformed cells, making it an excellent candidate for a cancer therapeutic. For example, 
expressing IL-24 in cells via an adenoviral vector induces apoptosis in melanoma cell 
lines in a p38MAPK-dependent manner, via activation of multiple members of the 
GADD family of genes113. Interestingly, though IL-24 acts as a secreted protein like other 
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cytokines, it also has some purported functions at the intracellular level. Expressing a 
non-secreted version of IL-24 (by deleting its signal peptide) still results in effective and 
specific killing of carcinoma cell lines114.  
There are some types of cancer, however, that are more resistant to IL-24-induced 
apoptosis. Some pancreatic cancer cell lines have a decreased ability to convert IL-24 
mRNA into protein, leading to less effective IL-24-induced killing. When cells are 
treated with agents that increase levels of ROS, however, the ability to translate IL-24 is 
restored, and pancreatic cancer cells undergo apoptosis115. This finding suggests that even 
tumor types that appear to be more resistant to IL-24-induced killing may be selectively 
killed with combination therapies. Interestingly, IL-24 has also been shown to increase 
ROS by inhibiting Nrf2 activation of antioxidant responses104, indicating a possible feed-
forward mechanism. 
IL-24 may be able to exert even stronger anti-tumor effects when expressed by 
normal cells. That is to say, normal cells that are adjacent to tumor cells could be used to 
potentiate a bystander tumor cell-killing effect, creating a more effective treatment while 
simultaneously removing the need to specifically target tumor cells with IL-24-
expressing adenoviral vectors116,117. It is also possible that IL-24 has the ability to 
upregulate itself in an autocrine manner, by increasing stability of IL-24 mRNA114, 
further potentiating the effects of IL-24 expression and decreasing the required amount of 
IL-24 expression. 
Many different human tumor types can be effectively killed by adenovirus-
mediated IL-24 expression (in vitro and in vivo) including lung cancer118, breast 
cancer119, and melanoma113, among others. In fact, clinical trials using injections of a 
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non-replicating adenoviral vector expressing IL-24 (INGN 241) have yielded promising 
results. A phase I study of the effects on intratumoral injection of INGN 241 in patients 
with advanced carcinoma showed effective expression of IL-24 mRNA and protein, wide 
distribution of IL-24 protein, and that the treatment induced apoptosis in a large 
percentage of the tumor cells, while also being well-tolerated120. Interestingly, there have 
been many different reported mechanisms of IL-24-induced apoptosis, including 
generation of ROS and ceramide121, induction of growth arrest and DNA damage 
(GADD)-inducible genes113, and suppression of Bcl-2 expression122. IL-24 
radiosensitizes cancer cells123, suggesting that in cases where IL-24 upregulation is 
insufficient to cause apoptosis, it can cooperate with damage caused by radiation to 
induce cancer cell death. Overall, IL-24 continues to represent a promising avenue of 
treatment for a variety of different cancers.  
 
Conclusions & Therapeutic Opportunities  
 The connection between aging and cancer is quite clear, though the mechanisms 
behind that connection still require further elucidation. Several mouse models and 
therapeutic strategies have been developed or proposed to manipulate some of these 
potential mechanisms.  
 One proposed strategy to remove senescent cells after cancer treatment involves 
synthetic lethal metabolic targeting of senescent cells124. Some lymphomas undergo 
senescence in response to chemotherapy, and have SASP-induced increases in glucose 
requirements and proteotoxic stress; thus, these senescent cells can be targeted by 
blocking glucose utilization or autophagy124. Other groups have shown that certain drugs 
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act as “senolytics,” or drugs that selectively target senescent cells, such as dasatinib and 
quercitin, and that these drugs extend healthspan and decrease frailty in mouse models of 
aging125. Rapamycin has also been presented as a potential anti-aging treatment, most 
recently because of its ability to prevent the senescence-associated inflammation caused 
by the SASP126. 
Some strategies for eliminating senescent cells have been tested in mouse models 
of premature aging. For example, the transgene INK-ATTAC was introduced into the 
BubR1 progeroid mouse model. This transgene allows for selective removal of p16Ink4a-
positive cells upon drug treatment, and was able to rescue some of the age-related 
phenotypes in the progeroid mice127.  
Overall, specifically targeting senescent cells and/or the SASP could alleviate 
many health issues, both aging- and cancer-related. These therapies would have to be 
very specific for the cells of interest, however, and could pose some potential problems. 
For example, blocking senescence may slow down or prevent symptoms of aging, but it 
would also destroy an important tumor suppression mechanism. On the other hand, 
increasing senescence may help treat or prevent cancer, but it may also contribute to 
aging. The ideal situation would be to selectively induce senescence, or to ensure 
clearance of senescent cells once they were induced (in cancer treatment), ensuring that 
senescent cells were still able to fulfill their physiological functions in wound healing, 
etc.  
Another way to control senescence and the SASP would be to target factors that 
regulate their induction. In order to do this, however, more details about their regulation 
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must be elucidated. Additionally, the nuances of general stress responses, in contrast to 
senescence- and SASP-related responses, must first be clarified.  
In the studies below, we investigate these stress responses using candidate genes 
upregulated in a microarray of damaged mouse cells. We sought to determine whether 
these upregulated genes that were not previously identified as part of the cellular stress 
response played a role in senescence, SASP, and/or a general response to genotoxic 
stress. Using cell culture systems of epithelial and fibroblast cells treated with a variety of 
different stressors, we identify IL-19 as a novel regulator of the SASP response, and IL-
24 as a novel responder to genotoxic stress. Both of these findings have the potential to 
impact the fields of aging and cancer in the future.  
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Summary  
The senescence-associated secretory phenotype (SASP) is a cellular stress response that 
modulates inflammation, tissue regeneration and tumor progression. Interleukin-1 (IL-1) 
is a master SASP regulator, controlling the expression of downstream SASP factors such 
as IL-6 and IL-8. However, the mechanism of IL-1 induction has remained unclear. 
Herein, we demonstrate that IL-19 is a SASP factor that operates as an upstream 
regulator of IL-1 and other SASP factors. In human epithelial cells and fibroblasts, we 
show that IL-19 transcript is upregulated up to 200-fold in response to diverse cellular 
stresses, including replicative exhaustion, oncogene expression, and ionizing radiation 
(IR). In response to IR, IL-19 induction is independent of IL-1 processing by the 
inflammasome and IL-1 receptor (IL-1R) engagement, but requires reactive oxygen 
species (ROS) and c-Jun N-terminal kinase (JNK) activation. Notably, suppression of IL-
19 expression inhibits the induction of IL-1 and other downstream SASP factors, 
indicating that IL-19 is required for induction of IL-1 in the SASP hierarchy. These 
findings identify IL-19 as a key extrinsic signaling factor that regulates a multitude of 
physiological processes in response to proliferative stresses and DNA damage. 
 
 
  
	  
	  
27	  
Introduction 
Cellular senescence is a protective mechanism that affects cancer progression, aging, 
and physiological processes such as wound healing and embryonic development128,129,130. 
The senescence-associated secretory phenotype (SASP), which occurs with senescence 
and other cellular responses to stress, mediates communication between senescent cells 
and proximal neighbors, including circulating immune cells29. The SASP reinforces 
growth arrest in senescent cells via secreted factors such as IL-631, and can also stimulate 
epithelial-mesenchymal transition and tumorigenesis in a paracrine fashion72. 
Additionally, senescent cells are linked to the chronic inflammation that occurs with 
advanced age131. Because senescence and the SASP play substantial roles in both aging 
and cancer, elucidating the mechanisms underlying these processes are critical for 
understanding both normal physiology and disease pathogenesis.  
Cellular senescence is stimulated by a variety of stress conditions, including 
oncogene expression, dysfunctional telomeres, and high levels of DNA damage. 
Interleukin-1α (IL-1α) has been identified as a master regulator of the SASP, as it 
initiates a feed-forward cascade of intrinsic (e.g. NF-κB) and secreted factors that amplify 
IL-1α production and stimulate downstream SASP factor expression, such as IL-6 and 
IL-832. Another important player in the activation of the SASP pathway is the 
inflammasome, a large protein complex that cleaves pro-IL-1 into an active protein 
form46,132. Beyond this processing, the upstream regulation of IL-1 stimulation as a part 
of the SASP has remained obscure. 
IL-19 is a member of the IL-10 cytokine family, which also includes IL-10, IL-20, 
IL-22, IL-24, and IL-2678. IL-19 is produced by multiple cell types, including myeloid 
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cells, keratinocytes, and B lymphocytes133. Current evidence suggests that IL-19 binds to 
an IL-20 receptor heterodimer composed of IL-20R1 and IL-20R2, and signals through 
the JAK-STAT pathway. Notably, the IL-20 receptor is present on a broad spectrum of 
stromal and epithelial cells80, suggesting a substantial physiological role for IL-19. 
Accordingly, IL-19 regulates wound healing in the skin by stimulating fibroblasts to 
secrete keratinocyte growth factor101. Normal regulatory functions in other tissues are 
clearly possible. 
IL-19 dysregulation is linked to psoriasis95, rheumatoid arthritis100, and inflammatory 
bowel disease97. In addition, many types of cancer express high levels of IL-19. Elevated 
expression of IL-19 is associated with poor prognosis in human breast cancer134,108 and 
correlates with advanced tumor stage and higher incidence of metastasis in esophageal 
squamous cell carcinoma109. Thus, determining the means of IL-19 regulation and its 
mechanism of action is important to better understand the etiology of cancer and other 
age-related diseases.  
We have previously shown that mosaic deletion of the ATR checkpoint kinase 
(ATRmKO) causes severe tissue regeneration defects that are exacerbated when p53-
dependent cellular clearance mechanisms are disrupted10,135. These tissue regeneration 
defects were accompanied by an acute inflammatory response135. These studies suggest 
that failure to remove ATR-deleted cells through normal apoptotic mechanisms leads to a 
non-cell autonomous response that impedes regeneration and stimulates the immune 
system to clear damaged cells135.  
In an effort to identify secreted factors in ATRmKOp53-/- tissues, we found that IL-19 
was prominently induced during regeneration, in concert with IL-1 and other SASP 
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factors. Herein, we report that IL-19 is upregulated by a variety of cellular stresses, 
including ionizing radiation (IR), oncogenic stress, and passage-induced senescence. 
Remarkably, unlike most SASP factors, IL-19 is regulated neither by IL-1 receptor 
engagement nor by signaling events associated with IL-1 production. Rather, we report 
that IL-19 upregulation is required for IL-1 and IL-6 induction and is dependent on 
oxidative stress and the JNK kinase. These data indicate that IL-19 is a key upstream 
regulator of secreted factor responses in a variety of cellular stresses. 
 
Results 
 
IL-19 is Upregulated in Response to Ionizing Radiation, Double-Strand Breaks 
(DSBs), Replicative Senescence, and Oncogenic Stress 
We hypothesized that the acute inflammation associated with tissue regeneration in 
ATRmKOp53-/- mice is caused by secreted factors produced by persistent ATRΔ/-p53-/- 
cells. To examine this possibility, ATRflox allele was deleted in the skin of the ATRflox/-
p53-/- and ATRflox/+p53-/- control mice and hair follicle regeneration was induced by 
depilation, as described135. At an early stage in follicle regeneration (days 4-6 post-
depilation), epithelial cells (α-6-integrin positive) in the S and G2 phases of the cell cycle 
(Hoechst live-cell staining) were isolated by FACS (data not shown). Phospho-H2AX, a 
marker of DNA damage, appears in ATRΔ/-p53-/- follicle epithelial cells at this stage, a 
few days prior to the onset of overt inflammation135. mRNA was isolated from these 
enriched populations and analyzed for gene expression changes between ATRΔ/-p53-/- and 
ATRΔ/+p53-/- skin by microarray. Multiple SASP factors, including IL-1β, CXCL2, and 
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MMP13 were increased in ATRΔ/-p53-/- skin (Table S2.1). However, IL-19, which had not 
been previously identified as a SASP or DNA-damage response factor, was also 
significantly upregulated (5.3-fold) compared to control cells (Table S2.1). 
We next examined whether IL-19 was generally upregulated by stresses known to 
induce SASP factors: double strand breaks (DSBs), passage-induced senescence, and 
oncogene expression. To test the ability of DSBs to stimulate IL-19 expression, normal 
human mammary epithelial cells (MCF10A) were treated with 10 Gy of IR, and IL-19 
mRNA levels were measured daily over a period of five days. Remarkably, IL-19 mRNA 
levels increased within 24 hours (Figure S2.1) and reached a maximum of 200-fold over 
basal expression within 3 days (Figure 2.1A). Similar increases were seen in the human 
breast adenocarcinoma (MDA-MB-231) and human pancreatic adenocarcinoma (BxPc3) 
cell lines (Figure 2.1A), indicating that the IL-19 response to IR occurs in both 
untransformed (MCF10A) and transformed (MDA231 and BxPc3) cell types. IL-19 
induction was reflected in increased protein levels (Figure 2.1B). Although IL-19 mRNA 
and protein increase concomitantly within 24 hours (Figure S2.1 and Figure 2.1B), IL-19 
protein peaks prior to mRNA, suggesting the employment of post-transcriptional control 
mechanisms. Other DSB-inducing treatments also caused a significant upregulation of 
IL-19 mRNA levels, as demonstrated by either a brief pulse (4 hours) or continuous 
treatment with etoposide (Figure 2.1C).  
The effects of replicative senescence and oncogenic stress on IL-19 levels were next 
examined in human primary fibroblast cell lines, which have intact p16INK4A loci and are 
capable of senescence-associated growth arrest. In all three cell lines tested (IMR90, 
MRC5, and WI-38), significant increases in IL-19 transcript levels were observed in late-
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passage senescent cells compared to early-passage controls (Figure2.2A). Senescence 
was confirmed through induced expression of p16INK4A and p21 (Figure 2.2B), increased 
SA-βgal staining (Figure S2.2), changes in cell morphology, and cell growth arrest. 
HRASG12V-driven oncogenic stress also led to a significant increase in IL-19 expression 
(Figure 2.2C). HRASG12V-expressing and non-expressing control cell lines were cultured 
in parallel and harvested upon the onset of HRASG12V-associated morphological changes 
and proliferation defects (8-12 days). All three HRASG12V-expressing fibroblast lines 
exhibited significant increases in IL-19 expression in comparison to controls. Notably, 
IL-19 induction occurred prior to increased expression of INK4A in both HRASG12V-
expressing IMR90 and MRC5 cells, indicating that IL-19 expression can precede the 
expression of INK4A in the course of oncogene-induced senescence (OIS).  
Taken together, these results demonstrate that IL-19 expression is stimulated by a 
variety of cellular stresses associated with SASP induction, including IR, DSBs, telomere 
uncapping (replicative senescence), and oncogenic stress. Furthermore, like the SASP30, 
IL-19 upregulation can occur in the presence or absence of senescence-associated growth 
arrest, as demonstrated by induction in both primary fibroblasts and INK4A- and p53-
mutant cell lines (MDA231 and BxPc3). 
 
IL-19 Is Regulated Independently of IL-1α and the Inflammasome 
As noted above, the timing of IL-19 mRNA induction closely matched that of several 
known SASP factors, including IL-1α, IL-1β, and IL-6 (Figure 2.3A, and data not 
shown). It has previously been demonstrated that IL-1α initiates a positive feedback loop 
that drives both IL-1 and downstream SASP factor expression. For example, engagement 
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of the IL-1 receptor (IL-1R) bolsters expression of IL-1, but also stimulates the 
expression of IL-6 and other SASP factors136. Given the prominent role of IL-1 in SASP 
regulation, we reasoned that IL-19 induction was likely downstream of IL-1 production 
and IL-1R engagement. 
To determine the role of IL-1R signaling in IL-19 induction, MCF10As were treated 
with an IL-1 receptor antagonist (rhIL-1RA) prior to IR treatment. This antagonist is 
sufficient to limit IL-1R activation from IL-1α and IL-1β binding, as well as to suppress 
subsequent IL-6 production. IL-1R blockade reduced the upregulation of IL-6 after IR 
treatment as expected (Figure 2.3B, left), however, it did not significantly decrease IL-19 
induction (Figure 2.3B, right). Similar results were observed using an IL-1α neutralizing 
antibody (data not shown). These findings indicate that IL-19 upregulation in response to 
IR is independent of IL-1R activation.  
 Both IL-1α and IL-1β can be processed by the inflammasome, a large protein 
complex that includes caspase-1 and is required for efficient IL-1 and SASP 
induction132,46. To determine if the inflammasome is necessary for IL-19 expression, 
MCF10As were irradiated and cultured in the presence or absence of a caspase-1 
inhibitor, Q-VD-OPh (QVD). Two days later, mRNA levels of IL-1α, IL-6, and IL-19 
were measured by qRT-PCR. As previously reported, the caspase-1 inhibitor suppressed 
upregulation of IL-1α and IL-6 (Figure 2.3C, left and middle). In contrast, IL-19 
induction was unaffected by caspase-1 inhibitor treatment (Figure 2.3C, right). Therefore, 
IL-19 regulation is independent of the IL-1/inflammasome-initiated SASP pathway, 
consistent with a model that IL-19 induction in response to IR is regulated by a pathway 
that is parallel to or upstream of IL-1 production. 
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IL-19 Induction Does Not Require ATM, DNA-PK, or p38MAPK Signaling 
The induction of certain SASP factors has been reported to require p38MAPK or 
ATM signaling38. p38MAPK activity is both necessary and sufficient for the expression 
of multiple SASP factors, and operates at least partly through the NF-κB pathway. 
Furthermore, p38MAPK is robustly activated by IR, as determined by phosphorylation of 
its downstream target MAPKAPK2 (MK2, Figure 2.4C). Induction of some SASP factors 
has been reported to be dependent on ATM, and it is possible that DNA-PK plays a 
compensatory role in this pathway when the ATM pathway is inhibited.  
To further characterize the signaling pathways that lead to IL-19 and IL-1 induction 
in response to IR, MCF10As were irradiated or treated with etoposide in either the 
presence or the absence of SB203580 (p38MAPK inhibitor), KU55933 (ATM inhibitor), 
and NU7026 (DNA-PK inhibitor), and IL-19 and IL-1α expression were quantified 2-3 
days later. While each inhibitor prevented phosphorylation of known substrates of these 
kinases (MK2: p38MAPK; H2AX: ATM and DNA-PK; Figures 2.4C and S2.3), and 
SB203580 prevented full induction of IL-1α expression (Figure 2.4D), these inhibitors 
had no significant effect on IR- or etoposide-induced IL-19 expression (Figure 2.4A, 
2.4B, and 2.4D right, respectively). In fact, treatment with the ATM and/or DNA-PK 
inhibitor treatment caused a small but significant increase in IL-19 mRNA in the treated 
cells (Figure 2.4A and 2.4B), and similar results were observed using selective ATR 
inhibitors (data not shown). These results indicate that p38MAPK, ATM, and DNA-PK 
are not required for IL-19 induction, again indicating that IL-19 regulation in response to 
IR is distinct from that of IL-1. 
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IR Induces IL-19 via ROS and JNK Signaling  
Although IR causes DSBs, which subsequently activate ATM and DNA-PK, the lack 
of a requirement for these kinases in IL-19 induction led us to postulate alternative means 
of IL-19 regulation. In addition to causing DSBs, IR also directly generates reactive 
oxygen species (ROS). Interestingly, oxidative stress is involved in replicative 
senescence54,137, and is sufficient to cause cellular senescence138,56,139. Therefore, we 
hypothesized that ROS may function in the IL-19 response to IR.  
To test the requirement for ROS in IL-19 induction, MCF10A cells were irradiated in 
the presence or absence of the ROS scavenger N-acetyl-cysteine (NAC), and IL-19 
mRNA was quantified 2-3 days later. In contrast to p38MAPK and PIKK inhibitors, 
NAC addition greatly reduced IR-induced IL-19 production (Figure 2.5A). Similar results 
were seen using Trolox, a distinct ROS scavenger (Figure 2.5B), and DMSO, which acts 
as a non-specific ROS scavenger at the high concentrations used (data not shown). To 
test whether oxidative stress is sufficient for IL-19 induction, MCF10As were pulsed 
with hydrogen peroxide (H2O2) for 30 minutes. This treatment caused a 20-fold induction 
of IL-19 (Figure 2.5C, left), and similar results were seen with another ROS-inducer, tert-
butyl hydroperoxide (TBHP, Figure 2.5C, right). Thus, IL-19 induction by IR requires 
ROS, and induction of ROS is sufficient to stimulate an IL-19 response. 
Because the kinase activity of the key DSB response proteins ATM, DNA-PK, and 
ATR was not required for IL-19 induction in response to IR or etoposide, we reasoned 
that ROS might regulate IL-19 independently of DNA damage. Indeed, ROS have been 
shown to directly activate numerous downstream regulators, that includes c-Jun N-
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terminal kinase (JNK)140. To test whether IL-19 induction in response to IR depends on 
the ROS-JNK pathway, MCF10As were irradiated in the presence or absence of the 
selective JNK inhibitor SP600125. JNK activity increased following IR treatment of 
MCF10A cells, as measured by phosphorylation of its downstream target c-Jun (Figure 
2.6A). This increase was suppressed by treatment with either the JNK kinase inhibitor 
SP600125 or the ROS scavenger N-acetyl cysteine (NAC) (Figure 2.6A and data not 
shown). Importantly, JNK inhibition significantly suppressed IL-19 induction by IR 
(Figure 2.6B). Taken together, these data show that following irradiation, ROS and 
downstream activation of the JNK kinase are required for the induction of IL-19.  
 
IL-19 Is Required for Induction of IL-1 and IL-6 Following IR Treatment 
The findings described above indicate that IL-19 is not dependent on IL-1R 
engagement or IL-1 production and that the signaling pathways that cause IL-19 and IL-1 
expression in response to IR are mechanistically distinct. Therefore, IL-19 and IL-1 
induction may occur independently of one another in parallel, or IL-19 could operate 
upstream of IL-1 production in the SASP response. Consistent with the latter possibility, 
the timing of IL-19 mRNA induction in response to IR closely correlated with that of IL-
1 at 2-3 days (Figure 2.3A). Time courses of IL-19 and SASP factor mRNA induction 
during passage-induced senescence and oncogene-induced senescence also showed a 
close temporal correlation between IL-19, IL-1, and IL-6 (Figures S2.4-S2.7). Moreover, 
IL-1 and IL-6 expression was suppressed by JNK inhibition and ROS scavenging, similar 
to IL-19 expression (Figure 2.6C and data not shown). According to this hypothesis, IL-
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19 expression should be required for IL-1 induction and the production of downstream 
SASP factors, such as IL-6 and IL-8, following IR treatment. 
To determine IL-19’s role in SASP factor regulation, MCF10As were engineered to 
express either a doxycycline (dox)-inducible shRNA that targets IL-19 expression 
(TRIPZ-shIL-19) or a verified non-targeting control shRNA (TRIPZ-shNT). Cells were 
treated with three different concentrations of dox, irradiated and then quantified for IL-
19, IL-1, and IL-8 mRNA levels three days later. Remarkably, dose-dependent 
suppression of IL-19 expression resulted in similar repression of IL-1α, IL-1β and IL-8 
induction in response to IR (Figure 2.7). These data suggest that IL-19 is required for the 
timely expression of SASP factors after IR treatment.  
To validate these findings, two distinct IL-19-targeting shRNAs were introduced into 
MCF10A cells through constitutive U6 promoter-driven expression (Figure 2.8). IL-19 
levels were measured by qRT-PCR over a time course of four days after IR treatment. 
Once again, suppression of IL-19 upregulation by IL-19 targeting shRNAs was sufficient 
to blunt upregulation of the downstream SASP factors IL-1α, IL-1β, and IL-6 following 
IR treatment (Figure 2.8), and the level of reduction of SASP factor induction roughly 
matched the level of IL-19 reduction. SASP factor reduction was not observed using 
multiple non-targeting control shRNAs (Figure 2.8 and data not shown). These results 
were repeated in the MDA231 cell line (Figure 2.9). Taken together, these data indicate 
that IL-19 is regulated by a mechanism that is distinct from IL-1, and that IL-19 induction 
is required for robust induction of IL-1 and other downstream SASP factors in response 
to IR (Figure 2.10).  
Discussion 
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Our findings demonstrate for the first time that IL-19 is a SASP factor that is required 
for efficient upregulation of key downstream factors, such as IL-1 and IL-6, in response 
to IR. Furthermore, we demonstrate that IL-19 induction is dependent on ROS and JNK, 
a means of regulation that is independent of IL-1 receptor engagement. IL-19 was not 
among the original 120 SASP candidates assayed by antibody arrays and is less well 
characterized than many other cytokines. Our identification of IL-19 as a regulator of the 
SASP provides novel mechanistic insight into the roles of IL-19 in the pathophysiology 
and treatment of several age-related diseases, including cancer. 
An intriguing aspect of our findings is the independence of IL-19 induction from 
regulation by the DNA-damage response proteins ATM and DNA-PK, and dependence 
on the ROS-JNK pathway in response to IR treatment. While these results are in apparent 
contrast to a previously reported role for ATM in SASP regulation, it has been reported 
that ATM inhibition can promote IL-6 upregulation in some contexts141, an effect that is 
in accord with our observation that ATM inhibition amplifies IL-19 expression (Figure 
2.4A, 2.4B). Alternatively, the positioning of IL-19 upstream of IL-1 induction affords 
the possibility that ATM participates in SASP at stages subsequent to IL-19 expression. 
Additional research will be required to dissect ATM’s role in the SASP. 
Gamma rays ionize water to generate ROS, which mediate a number of intracellular 
signaling events, including the JNK pathway activation142,140 (Figure 2.4C). Interestingly, 
it is possible that increases in ROS and hyperactivation of other MAPK-regulated 
signaling pathways function in oncogene-driven upregulation of IL-19, as each of these 
signaling events are associated with oncogene expression54. Indeed, these pathways may 
serve as common intermediates in SASP induction and provide a mechanism by which 
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oxidative stress promotes replicative senescence138,143 and contributes to senescent cell 
bystander effects47. 
IL-19 expression and secretion is associated with a variety of inflammatory disorders 
in humans, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis144. 
For example, IL-19 mRNA levels are significantly higher in synovial fluid mononuclear 
cells of patients with rheumatoid arthritis as compared to healthy volunteers and patients 
with osteoarthritis. Furthermore, IL-19-producing cells are increased in the intestine in 
patients with active Crohn’s disease in comparison with non-inflamed tissues. IL-19 is 
also involved in tissue regeneration following stress. Despite the potential for abnormal 
compensation by other IL-10 family members, IL-19-deficient mice are susceptible to 
dextran sodium sulfate-induced colitis, have reduced B-cell recruitment during chronic 
colitis, and exhibit defective angiogenesis after ischemic injury98,102. Interestingly, 
sudden transition from normoxic to hypoxic conditions causes acute increases in ROS145, 
which may be involved in stimulating IL-19 expression following ischemic injury.   
Based on our findings, IL-19 could also play important roles in cancer etiology and 
the effectiveness of treatment. The cancer-promoting effects of inflammation, as well as 
the well-documented growth-promoting and pro-survival effects of IL-6 in the tumor 
microenvironment, imply that IL-19 may play a significant role in tumorigenesis. Indeed, 
because of the link to IL-6 induction, IL-19 would also be expected to facilitate 
epithelial-mesenchymal transition and metastasis. Thus, our findings provide an 
important link for the known association between high levels of IL-19 expression and 
poor prognosis in breast cancers and rapid progression and metastasis in esophageal 
cancers. Finally, our studies indicate that the well-documented pro-survival effects of IL-
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6 following treatment with IR and DNA-damaging treatments70 are dependent on IL-19. 
Therefore, blockade of IL-19 may improve the efficacy of such treatments. Overall, our 
findings indicate an important role for IL-19 in cancer treatment and etiology, and the 
onset of other age-associated pathologies, functions that may in the future be adapted to 
improve human healthspan. 
 
Experimental Procedures 
Cell Lines and Staining Methods. MCF10A and MDA-MB-231 human mammary 
epithelial cells were cultured as described146. IMR90, MRC5, and WI-38 human 
fibroblast cell lines were obtained from the Coriell Cell Repository (Camden, NJ) and 
cultured in DMEM with 15% FBS, 1X penicillin and streptomycin, and 1 ug/ml 
amphotericin B in a 3% O2 and 6% CO2 atmosphere at 37°C. BxPc3 human pancreatic 
epithelial cells were cultured in DMEM supplemented with 10% FBS, 100 units/ml 
penicillin, 100 ug/ml streptomycin, and 5% fungizone. SA-βGal staining was performed 
as described147. 
Viruses and Infections. To generate lentiviruses, HEK293T cells were transfected using 
the calcium phosphate precipitation of the lentiviral expression vector with pMDL, 
pVSVG, and pRSV-REV for pLKO.1 lentivirus production or psPAX2 and pMD2.G for 
pTRIPZ lentivirus production. To generate retroviruses, HEK293T cells were transfected 
using the calcium phosphate method with the retroviral expression vector and a ψ2 
vector. pLKO.1 vectors expressing IL-19 shRNA #1 
(TATCAGTATTGTACCCAGGAG) and IL-19 shRNA #2 
(ATTTGGGAAGGTGTCCTTAGC) were purchased from Open Biosystems 
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(TRCN0000058726 and TRCN0000058727, respectively). The specific sequences of 
non-targeting shRNAs expressed from pLKO.1 vectors are as follows: 
CAACAAGATGAAGAGCACCAA and CCTAAGGTTAAGTCGCCCTCG (Addgene 
plasmid #1864). Lentiviral-infected cells were selected for 1-2 days with puromycin. 
TRIPZ-inducible non-silencing shRNA control and IL-19-targeting shRNA lentiviral 
vectors were obtained from Open Biosystems (Cat # RHS4743 and RHS4696-
200675014, respectively). Control and HRASG12V pBABE retroviral vectors were 
purchased from Addgene (#1764 and #9051, respectively). 
ELISA. Intracellular protein levels of IL-19 were determined by lysing cells in extraction 
buffer and collecting the soluble supernatants after centrifugation at 13,000 RPM as 
described (Abcam). ELISAs were performed as described (R&D Systems, #DY1035). 
ELISA values were normalized by cell number.  
Real-time quantitative PCR. Cells were lysed and RNA was isolated using the GeneJet 
RNA purification kit (Fermentas Life Sciences #K0731). Reverse transcription was 
performed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems Inc. #4368814). Quantitative PCR was then performed using Sybr Green 
PCR Master Mix (Applied Biosystems Inc. #4309155) or TaqMan Gene Expression 
Master Mix (Applied Biosystems Inc. #4304437). IL-19 primer/probe set was purchased 
from Invitrogen (#4331182). Other primer sets are as follows: 
Gene Forward Primer Reverse Primer 
IL-1α AACCAGTGCTGCTGAAGGA TTCTTAGTGCCGTGAGTTTCC 
IL-1β GGCCCTAAACAGATGAAGTG TGCCGCCATCCAGAGG 
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CT 
IL-6 CCAGGAGCCCAGCTATGAAC CCCAGGGAGAAGGCAACTG 
IL-8 TTGGCAGCCTTCCTGATTTC 
TCTTTAGCACTCCTTGGCAAA
AC 
p16INK4
A 
GGGTCGGGTAGAGGAGGTG GCCTCCGACCGTAACTATTCG 
p21 GCGATGGAACTTCGACTTTGT GGGCTTCCTCTTGGAGAAGAT 
GAPDH 
CGAATTTGGCTACAGCAACAG
G 
GTACATGACAAGGTGCGGCTC 
 
Western Blotting. Following direct addition of Laemmeli sample buffer, whole cell 
lysates were vortexed briefly, boiled at 98°C for 5 minutes, loaded on 4-20% gradient 
SDS-polyacrylamide gels (Thermo Scientific #0025244), and separated by 
electrophoresis. Proteins were then transferred to PVDF membranes, blocked in 5% milk 
in TBST for 1 hour at RT, bound to primary antibodies in blocking buffer (4°C 
overnight), washed, and then detected with horseradish peroxidase-conjugated secondary 
antibodies and chemiluminescence (Thermo Scientific #34080).  
Antibodies. Anti-MAPKAPK-2 and anti-phospho-MAPKAPK-2 were purchased from 
Cell Signaling Technology (Cat #3042P and #3007P, respectively). Anti-GAPDH was 
purchased from US Biological (Cat #G8140). Anti-c-Jun and anti-phospho-c-Jun were 
purchased from Cell Signaling (Cat #9165P and #2361P, respectively). Anti-phospho-
H2AX (Ser139) was purchased from Millipore (Cat #05-636). 
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Chemicals and Inhibitors. ATM inhibitor (KU55933), DNA-PK inhibitor II (NU7026), 
and ATR inhibitor148 (CAS Registry Number: 1233339-36-0) were purchased from 
Calbiochem (Cat #118500 and #260961) or synthesized148. p38MAPK (SB203580) and 
JNK (SP600125) inhibitors were purchased from Selleckchem (Cat #S1076) and Sigma 
Aldrich (Cat #S5567), respectively. Recombinant human IL-1 receptor antagonist (rhIL-
1RA) and Caspase-1 inhibitor (InSolution Q-VD-OPh) were purchased from R&D 
Systems (Cat #280-RA) and EMD Millipore (Cat #551476), respectively. N-
Acetylcysteine and Trolox were purchased from Sigma (Cat #A9165) and Santa Cruz 
Biotechnology (Cat #sc-200810), respectively. 
Statistics. To determine significance at specific time points, an unpaired, 2-tailed 
Student’s t-test was used. For time courses, regression analyses of lines were performed 
by quadratic (second-order polynomial) linear model using the following equation: Y=B0 
+ B1x + B2x2, where x is days post-irradiation and B0, B1, and B2 are regression 
coefficients. All modeling and analysis was performed using Graphpad Prism v 6.0 (La 
Jolla, CA) with P values of less than 0.05 considered significant.  
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Figure Legends 
Figure 2.1. IL-19 is upregulated following clastogenic treatment. (A) Fold change in IL-
19 transcript levels in human breast (left and right) and pancreatic (middle) epithelial 
cells in response to IR (10 Gy) compared to non-irradiated controls as quantified by qRT-
PCR and normalized to GAPDH expression (n=6-26, means +/- SE by t-test are shown). 
(B) IL-19 protein levels in irradiated (10 Gy) MCF10A cells as quantified by ELISA 
(n=6-12). (C) IL-19 transcript levels induced by 20 µM etoposide in MCF10As (n=9-12).  
Figure 2.2. IL-19 is upregulated following replicative senescence and oncogenic stress. 
(A and B) IL-19 mRNA (A) and p16INK4A and p21 mRNA levels (B) in early passage 
vs. late passage fibroblasts (n=3). (C) Relative IL-19 and p16INK4A transcript levels in 
human fibroblasts exposed to HRASG12V-induced oncogenic stress, compared to empty 
control-infected cells, collected between 8-12 days after infection (control and HRASG12V 
cells were collected at the same day for each cell type), normalized to GAPDH  (n=4-11).  
Figure 2.3. IL-19 is independent of IL-1 signaling. (A) Time course of interleukin 
mRNA induction after IR compared to non-irradiated controls, normalized to GAPDH. 
(B) Effect of 1.0 µg/ml rhIL-1 receptor antagonist (rhIL-1RA) on IL-6 and IL-19 mRNA 
levels in response to 10 Gy IR, compared to non-irradiated vehicle controls, normalized 
by GAPDH (n=8-9, means +/- SE by t-test are shown). Cells were treated with rhIL-1RA 
beginning immediately before IR, and rhIL-1RA was kept in the media until collection of 
cells at 48 hours after IR. (C) Effect of caspase inhibitor (QVD) on IL-1α, IL-6, and IL-
19 induction 48 hours after 10 Gy IR, measured and normalized as in Figure 2.3A (n=7-
9). Inhibitor was used at 20 µM and replenished every 24 hours. 
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Figure 2.4. IL-19 is independent of ATM, DNA-PK, and p38MAPK signaling. (A and B) 
Changes in IL-19 mRNA levels in MCF10A cells in the context of ATM and DNA-PK 
inhibition following 10 Gy irradiation (A, n=8-9) or 20 µM etoposide treatment (B, n=8-
12). ATM inhibitor, DNA-PK inhibitor, and etoposide were used at 10 µM, 10 µM, and 
20 µM, respectively. Cells were pre-treated with ATM and/or DNA-PK inhibitor for 30 
minutes before IR, and drugs were replenished every 24 hours. (C) Western blot 
detection of p38MAPK pathway activation, via phosphorylation of MAPKAP kinase 2 
(MK2), following 10 Gy IR in the presence or absence of p38MAPK inhibitor. Cells 
were pre-treated with 10 µM p38MAPK inhibitor for 30 mins before IR. Inhibitor was 
replaced every 24 hours to ensure effective inhibition of the SASP as previously shown38, 
and cells were collected and lysed 48 hours after IR. (D) Fold induction of IL-19 and IL-
1α mRNA after 10 Gy IR in the presence of 10 µM p38MAPK inhibitor, quantified and 
normalized as in Figure 2.2A (n=8-9). Additional data are shown in Figure S2.3. 
Figure 2.5. IL-19 induction is dependent on oxidative stress. (A and B) IL-19 mRNA in 
MCF10As irradiated and treated with the ROS scavengers NAC (A, n=8-9, means +/- SE 
by t-test are shown) or Trolox (B, n=7-9). (C) IL-19 transcript levels in MCF10As pulsed 
with 250 µM hydrogen peroxide for 30 mins, washed, and then collected 3 days later 
(n=9) or TBHP (n=6-9).  
Figure 2.6. IL-19 induction is dependent on JNK signaling. (A) Western blot detection of 
phospho-c-Jun and total c-Jun in whole-cell lysates of MCF10A cells treated with 10 Gy 
IR in the presence or absence of 10 uM JNK inhibitor. (B and C) Fold change in IL-19 
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(B) and SASP factors IL-1α, IL-1β, and IL-6 (C) mRNA in MCF10As irradiated in the 
presence or absence of 10 uM JNK inhibitor (n=8-12). 
Figure 2.7. IL-19 is required for SASP factor induction. IL-19 knockdown and SASP 
factor induction in MCF10A cells infected with dox-inducible TRIPZ vectors expressing 
control or IL-19 shRNAs and treated with dox and 10 Gy IR, analyzed by qRT-PCR, 
compared to non-induced, non-irradiated cells (means +/- SE; p-values were calculated 
by Student’s t-test). Doses of dox used were 0.1 µg/ml (+), 0.5 µg/ml (++), and 1.0 µg/ml 
(+++). Cells were pre-treated with dox 24 hours before IR, and dox was replenished 
every 48 hours thereafter until collection at 3 days post-IR. 
Figure 2.8. IL-19 is required for SASP factor induction in MCF10As. IL-19 knockdown 
and SASP factor induction in MCF10A cells infected with constitutively expressing 
control or IL-19 shRNAs (means +/- SE; p-values were calculated using linear regression 
of the whole time course. See Statistical Methods section and Figure S2.8). 
Figure 2.9. IL-19 is required for SASP factor induction in MDA231s. IL-19 knockdown 
and SASP factor induction in MDA231 cells infected with constitutively expressing 
control or IL-19 shRNAs (means +/- SE; p-values were calculated using linear regression 
of the whole time course. See Statistical Methods section and Figure S2.9). 
Figure 2.10. Model of IL-19’s role in the SASP 
Table S2.1. Fold change in mRNA levels in ATRflox/-Cre-ERT2+ and ATRflox/+Cre-
ERT2+ mouse epithelial cells (α-integrin+) 4-6 days after topical 4-OHT treatment. 
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Figure S2.1. Induction of IL-19 mRNA 24 hours after IR. Magnified view of first two 
data points in Figure 1A illustrating upregulation of IL-19 mRNA within the first 24 
hours of IR treatment. P-values as calculated by Student’s t-test are shown. 
Figure S2.2. SA-βgal staining of fibroblasts. (A and B) Representative images (A) and 
quantification (B) of SA-βgal staining in early and late passage fibroblasts. P values were 
calculated using the Student’s t-test.  
Figure S2.3. Controls demonstrating small molecule inhibition of ATM and DNA-PK 
kinase activity. (A) Control Western blot demonstrating a decrease in γH2AX levels with 
addition of 10 µM ATM inhibitor. (B) Control Western blot showing a decrease in 
γH2AX levels in a dose-dependent manner with the addition of DNA-PK inhibitor, in the 
presence of 2.5 µM camptothecin, 5 µM ATR inhibitor, and 10 µM ATM inhibitor, as 
described149.  
Figures S2.4-S2.6. SASP factor induction follows or coincides with IL-19 induction in 
passage-induced senescent fibroblasts. Human fibroblast lines IMR90 (S4), MRC5 (S5), 
and WI38 (S6) were cultured and split serially 1:1, with half of the cells collected at each 
time point. Cells were then lysed and analyzed for levels of IL-19, p16INK4a, and/or 
SASP factor mRNA by qRT-PCR, normalized to GAPDH levels. Each data point 
represents one sample.  
Figure S2.7. IL-19 mRNA peaks 1-2 days before IL-1 mRNA. IMR90 cells were 
infected with empty vector control or HRASG12V and cultured for 0-14 days after 
infection. Cells were collected every two days, lysed and analyzed for IL-19 or IL-1α 
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induction by qRT-PCR. mRNA levels were normalized to GAPDH. N=3 for each time 
point. Day 4 IL-19 data was excluded because cells were selected with puromycin from 
day 2 to day 4, which in itself causes IL-19 induction (comparable IL-19 induction is 
seen in both control and HRASG12V cells).  
Figure S2.8. Curves and values used to calculate P values in Figure 2.8. 
Figure S2.9. Curves and values used to calculate P values in Figure 2.9. 
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Figure 2.1 
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Figure 2.2 
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Figure 2.3 
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Figure 2.4 
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Figure 2.5 
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Figure 2.6 
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Figure 2.7 
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Figure 2.8 
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Figure 2.9 
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Figure 2.10 
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Table S2.1 
 
 
 
  
Table"S2.1"
Gene Name 
Gene 
Symbol p-value 
Fold 
Change  
Interleukin 24 Il24 0.000732086 18.0269 
 Chemokine ligand 2 Cxcl2 0.00882865 5.98775 
 Matrix metallopeptidase 13 Mmp13 0.00493047 5.75109 
 Interleukin 1 beta Il1b 0.0125051 5.57743 
 Interleukin 19 Il19 0.011148 5.34224 
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Figure S2.1 
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Figure S2.2 
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Figure S2.3 
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Figure S2.4 
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Figure S2.5 
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Figure S2.6 
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Figure S2.7 
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Figure S2.8 
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Figure S2.9 
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CHAPTER 3: 
IL-24 is an acute S-phase damage-specific response protein that regulates cell 
survival 
 
Sara H. Small1, Eric J. Brown1 
 
1Abramson Family Cancer Research Institute and the Department of Cancer Biology 
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Summary 
 
As discussed above, cells are constantly subjected to different types of stress that cause 
DNA damage, including cell-autonomous (e.g. DNA replication stress) and cell non-
autonomous (e.g. UV radiation and ROS) stresses, potentially resulting in apoptosis or 
senescence, preventing highly damaged cells from becoming cancerous. The microarray 
we performed on damaged p53-/-ATRΔ/- epidermal cells has showed upregulation of a 
number of factors that may both invoke inflammation and regulate tissue regeneration 
(Chapter 2, Figure S2.1), including IL-24, the most highly induced factor. We validated 
this IL-24 induction in an in vitro system by treatment of a variety of mouse and human 
cell lines, both normal and transformed, with ATR inhibitors. By comparing the effects of 
treatment of human pancreatic epithelial cells with IR and a variety of chemical inhibitors 
that impact DNA synthesis, we have shown that the upregulation of IL-24 is specific to 
DNA-damage occurring during S-phase. Additionally, we have demonstrated a role for 
p38MAPK in the post-transcriptional regulation of the IL-24 transcript. We postulate IL-
24 upregulation serves as a mechanism for DNA damage-induced cell death in cancerous 
cells. 
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Introduction 
As described in Chapter 2, one known cellular response to cellular stress is 
senescence and activation of the senescence-associated secretory phenotype (SASP), 
whereby a cell exits the cell cycle but remains metabolically active, and secretes a variety 
of soluble factors. Some of these factors work in an autocrine manner to reinforce growth 
arrest31. Other factors serve to recruit inflammatory cells and promote tissue repair150. 
Similarly, apoptotic cells can release factors such as PGE2 that stimulate tissue 
regeneration151,152. Thus, both intrinsic and extrinsic factors from damaged cells can play 
a large role in tissue maintenance.  
ATR knockout mice display tissue regenerative defects, both during the clearance 
of ATR-deleted cells and after immediate compensatory renewal10. However, as 
described in Chapters 1 and 2, combining the ATR-null genotype with deletion of p53 
intensifies this regenerative delay135. Because p53-/-ATRΔ/- cells are more persistent in 
tissues than p53 wild-type ATRΔ/- cells, and because regeneration in each case is driven 
by residual ATR expressing cells, these results indicate that the failure of p53-/-ATRΔ/- 
cells to undergo programmed cell death causes the dominant inhibition of regeneration 
from ATR-expressing cells. Similar results are seen when p53 is deleted in telomere-
dysfunctional or Hus1 (an ATR-Chk1 pathway intermediate) knockout mice153,154. 
Therefore, while apoptotic cells stimulate renewal, persistent cells with a high degree of 
replication-associated damage inhibit regeneration. However, as senescent cells 
accumulate in tissues of aging organisms, they can affect the tissue microenvironment 
and promote a decline in tissue homeostasis during aging without a decrease in stem cell 
numbers6,155.  
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IL-24, also known as melanocyte differentiation-associated protein 7 (MDA-7), is 
an IL-10 family of cytokines member, and was first discovered in the context of 
melanoma. It was found that as melanocytes became transformed into melanoma, they 
downregulated IL-2484. Multiple groups have since shown that ectopically expressed IL-
24 (via an adenoviral expression system) can cause apoptosis in transformed, but not non-
transformed, cells117,156,119. IL-24 has also been shown to be secreted by various cell types 
during wound repair. Additionally, IL-24 can stimulate inflammation by inducing 
monocyte and neutrophil migration. As such, IL-24 is upregulated in a variety of human 
inflammatory disorders, including inflammatory bowel disease, rheumatoid arthritis, and 
psoriasis. IL-24 signals through two separate receptor heterodimers, IL-20R1/IL-20R2 
and IL-22R1/IL-20R2. IL-24 transgenic mice that overexpress IL-24 cDNA in the skin 
under the keratin 5 promoter display epidermal hyperplasia and significant recruitment of 
monocytes96. Thus, IL-24 was an attractive candidate as a contributor to the inflammatory 
phenotype seen in the p53-/-ATRΔ/- mouse skin cells. 
 Selective upregulation of IL-24 in response to replication-associated damage (ATR 
and DNA polymerase inhibition or topoisomerase I inhibition) was confirmed in vitro. 
We found that IL-24 upregulation was conserved across species and cell types, and that it 
occurs in a tightly regulated timeframe, peaking within 18 hours and quickly decreasing 
afterwards. IL-24 induction was independent of DNA damage response proteins ATR, 
ATM, and DNA-PK; in fact, inhibition of these proteins served to intensify the response. 
However, IL-24 induction was dependent on p38MAPK. Lastly, IL-24 knockdown 
decreased apoptosis caused by S-phase damage in mouse pancreatic intraepithelial 
neoplasia (PanIN) cells. 
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Results 
 
IL-24 is upregulated in multiple cell types in response to replication stress 
In order to examine IL-24’s role in the inflammatory and defective regeneration 
phenotype we observed in ATRmKO/-p53-/- mice, we first determined if IL-24 is 
upregulated in response to different types of stress in a cell culture model. ATRΔ/-p53-/- 
cells exhibit the most DNA damage in S-phase, as ATR is needed by cells mostly during 
DNA replication. In order to model the response to S-phase damage incurred by ATRΔ/-
p53-/- cells, we used a human pancreatic epithelial cell line with mutated p53 (220cys), 
BxPc3. BxPc3 cells were pulsed with the DNA polymerase inhibitor aphidicolin and/or 
ATR inhibitor ATR45 for 6 hours. We then washed out the inhibitors and allowed cells to 
recover for 1-72 hours. Cells were then collected, lysed, and qRT-PCR was performed to 
measure the induction of IL-24 and other DNA damage-induced factors. The other 
factors measured were SASP factors (IL-1β, IL-6, and IL-8) and other IL-10 family 
members (IL-19 and IL-20). Aphidicolin alone did not cause a significant upregulation of 
any of the measured factors (Figure 3.1A). ATR45 alone, however, caused a significant 
30-fold upregulation of IL-24 at the 18 hour time point (Figure 3.1B). Strikingly, the 
combination of aphidicolin and ATR inhibitor caused an even higher IL-24 upregulation 
at the 18 hour time point, approximately 90-fold (Figure 3.1C). In both cases where IL-24 
was induced, the mRNA increase was very rapid (not seen at 6 hours, peaking at 18 
hours, and decreasing significantly by 38 hours). Similar results were seen when cells 
were treated with aphidicolin and a structurally distinct ATR inhibitor, ATR-AZ.  
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In order to validate that these results were not specific to the BxPc3 cell line, and 
since IL-24 is known to be downregulated in melanoma cells, we performed similar 
experiments in WM239A cells, a human melanoma cell line. WM239A cells were treated 
with ATR-AZ plus aphidicolin, or DMSO control, for 6 hours. Cells were then washed to 
remove the DMSO and inhibitors, and cells were incubated for an additional 18 hours, 
since that was the time point showing the greatest IL-24 induction in the BxPc3 cells. 
Cells were then harvested and lysed for RNA extraction and subsequent qRT-PCR. As 
seen in the BxPc3 cells, the WM239A cells displayed a significant induction of IL-24 
mRNA. 
Lastly, to test whether the timing of IL-24 induction was conserved between 
species, we performed a time course on a mouse PanIN cell line (PI34 cells). PI34 cells 
were treated with ATR45 and aphidicolin for 6 hours, and collected 4-82 hours after 
wash-out. IL-24 induction was measured using two different sets of IL-24 qRT-PCR 
primers. Both IL-24 primers showed an IL-24 mRNA peak at the 18 hour time point 
(Figure 3.2B), as seen in the BxPc3 cells. Taken together, these results show that IL-24 is 
an acute response to DNA damage that is conserved in mouse and human cells. 
 
IL-24 is upregulated specifically in response to S-phase damage 
After determining that the IL-24 response is induced by replication stress, via 
ATR and DNA polymerase inhibition, we wanted to test whether IL-24 induction occurs 
in response to other types of DNA damage. We examined whether IL-24 was upregulated 
in cells undergoing apoptosis in general, or whether it was a specific response to damage. 
To answer this question, we treated BxPc3 cells with ATR-AZ and aphidicolin either 
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with or without the caspase inhibitor Q-VD-OPh (QVD) to prevent apoptosis. Cells were 
harvested 18 hr or 24 hrs after ATR-AZ and aphidicolin wash-out (QVD was kept in the 
media for the duration of the experiment) and analyzed by qRT-PCR for IL-24 levels 
(Figure 3). IL-24 induction was unchanged by the addition of QVD, suggesting that IL-
24 is not a non-specific response to the onset of apoptosis. 
We next tested another S-phase specific drug, the topoisomerase I inhibitor 
camptothecin (CPT). In order to find a dose of CPT that induced the same amount of 
DNA damage as the ATR45 inhibitor plus aphidicolin, BxPc3 cells were treated with 0.5, 
1, or 2.5 uM CPT for 1 or 6 hours (or ATR45 plus aphidicolin for comparison). Cells 
were then collected, lysed, and total cell lysates were used for Western blotting. BxPc3 
cells treated with 2.5 uM for 6 hours had similar levels of γH2AX to cells treated with 
ATR45 and aphidicolin (Figure 3.5A). Thus, for subsequent experiments with CPT, cells 
were treated with CPT for 6 hours, washed, and incubated in fresh media without CPT 
until collection. Similarly to the results seen with an ATR inhibitor with aphidicolin, cells 
treated with camptothecin showed a striking induction of IL-24 18 hours after CPT wash-
out (Figure 3C). These results, combined with those from Figure 1, suggest that IL-24 
induction is triggered most strongly by S-phase-specific DNA damage. 
While ATR and DNA polymerase inhibition and camptothecin cause DSBs in S-
phase indirectly via replication fork collapse, ionizing radiation (IR) causes DNA damage 
both directly and indirectly through the formation of reactive oxygen species (ROS). 
Thus, we irradiated BxPc3 cells with 10 Gy IR, collected cells at different time points, 
and measured IL-24 and other factor levels via qRT-PCR. While IL-6, IL-19, and IL-20 
were all induced starting within two days of irradiation, reaching a 10-fold maximal 
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increase by 70 hours after irradiation, IL-24 was induced to a very small degree, 
especially compared to its induction by ATR inhibitor with or without aphidicolin (Figure 
3.4A). Next, we treated cells with the topoisomerase II inhibitor etoposide, which causes 
double strand breaks in cells between S and G2 phases of the cell cycle. Similarly to IR, 
etoposide caused only a slight induction of IL-24 mRNA (Figure 3.4B).  
 
The IL-24 response is independent of DDR proteins and dependent on p38MAPK 
Once we characterized the type of damage required for and the temporal 
regulation of the IL-24 response, we next examined the mechanism of IL-24 
upregulation. Because IL-24 was induced in an S-phase-specific manner, in response to 
DNA damage, we first tested the DNA damage response kinases ATM and DNA-PK, 
which are activated in response to both camptothecin (Chapter 2, Figure S2.3) and ATR 
inhibition (Chapter 2, Figure S2.3). We pulsed BxPc3 cells with ATR-AZ and 
aphidicolin, with or without ATM and/or DNA-PK inhibition, and measured the 
transcript levels of IL-24 18 hours later via qRT-PCR. Surprisingly, the addition of ATM 
and/or DNA-PK inhibition intensified the IL-24 response to ATR and DNA polymerase 
inhibition (Figure 3.4A). Thus, not only is IL-24 induction independent of these DNA 
damage response kinases, but also they appear to at least partially suppress the IL-24 
response, perhaps by repairing the DNA damage (e.g. double strand breaks) that initiates 
the signaling leading to IL-24 induction. 
 As mentioned above, inhibition of ATM and/or DNA-PK intensified the IL-24 
response to ATR-AZ plus aphidicolin, approximately two-fold with the addition of DNA-
PK inhibitor, and approximately 3-fold when both DNA-PK inhibitor and ATM inhibitor 
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were present. Of note, in those experiments, ATR was inhibited only for the initial 6 hour 
pulse with aphidicolin, and was washed out during the 18 hour incubation afterwards 
(Figure 4B), leaving the possibility that ATR is still required for IL-24 induction. To test 
this possibility, cells were treated with ATR-AZ for either 6 hours or for the entire 
duration of the experiment, i.e. continuously (Cont), and with aphidicolin for 6 hours. 
Cells were collected 24 hours after ATR-AZ treatment began (equivalent to the “18 hour 
time point” in previous experiments), lysed, and analyzed by qRT-PCR for changes in 
IL-24 transcript levels. Surprisingly, the additional 18 hours of ATR-AZ treatment 
significantly intensified the IL-24 response, as the fold change in mRNA increased from 
approximately 100-fold to greater than 1600-fold. This striking increase in IL-24 
induction suggests that either ATR inhibition for the additional 18 hours causes a 
significant increase in the amount of DNA damage experienced by the cells 
(approximately 16-fold), or that ATR has an important role in suppressing IL-24 pathway 
activation in a more direct manner.  
 In order to test these possible roles for ATR in IL-24 induction, we treated cells 
with CPT to induce S-phase damage and/or ATR-AZ for 6 hours or continuously (as in 
the previous experiment), as well as with or without aphidicolin and the DNA-PK 
inhibitor. Cells were then collected and lysed at the 18 hour time point, and analyzed by 
western blotting (Figure 5). Membranes were blotted for γH2AX and phospho-Chk1 (Ser 
345) as surrogates for DNA damage and ATR activation, respectively. As seen in lanes 3 
and 4, treating cells with CPT and continuously with ATR-AZ versus 6 hours decreased 
phospho-Chk1 levels, as expected, but did not significantly increase levels of γH2AX. 
Similarly, as seen in lanes 7 and 8, treating cells with aphidicolin and continuously with 
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ATR-AZ versus 6 hours decreased phospho-Chk1 levels, but did not obviously increase 
levels of γH2AX. Adding in a DNA-PK inhibitor, as shown in lanes 9-11, also did not 
significantly increase the amount of γH2AX. Therefore, the increase in IL-24 when ATR 
is inhibited continuously (not for 6 hours only) cannot be attributed solely to an increase 
in DNA damage. The same logic follows when DNA-PK inhibition is added to the 
previous condition. These results suggest that ATR has a DNA damage-independent role 
in regulating IL-24 induction.  
 Because the DDR proteins ATR, ATM and DNA-PK were not required for IL-24 
induction by replication stress, we next turned to p38MAPK. p38MAPK is activated by 
DNA damage (Chapter 2, Figure 4), and has been reported to stabilize the IL-24 
transcript through specific 3’ UTR binding proteins111. In order to test whether 
p38MAPK has a role in IL-24 regulation in our system, we treated BxPc3 cells with 
ATR-AZ and aphidicolin for 6 hours in the presence or absence of the p38MAPK 
inhibitor SB203580, and measured mRNA levels of IL-24 6 hours and 18 hours later. 
Notably, the presence of the p38MAPK inhibitor almost completely abrogated IL-24 
induction from ATR-AZ and aphidicolin treatment (Figure 6). Thus, p38MAPK activity 
is required for IL-24 induction in our system. Importantly, p38MAPK may be required 
for the increase in IL-24 transcript at either the transcriptional or post-transcriptional 
level, since our results do not distinguish between a role for p38MAPK in IL-24 
induction and IL-24 transcript stabilization. 
 
Apoptosis from fork collapse is attributable to IL-24 in mouse PanIN cells 
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Because IL-24 has been shown to have a role in apoptosis induction in 
transformed cells, we wanted to test whether IL-24 was required for ATR inhibition-
induced apoptosis. Mouse PanIN cells (PI34) were infected with a control shRNA or one 
of two different IL-24 shRNAs. The resulting cells were treated with ATR-AZ and 
aphidicolin for 6 hours, washed to remove the inhibitors, and incubated with inhibitor-
free media and collected 16, 20, or 24 hours later. Based on our previous experiments, 
these time points corresponds to approximately 2 hours before, 2 hours after, and 6 hours 
after the peak of IL-24 mRNA, respectively. Cells expressing either IL-24 shRNA #1 or 
shRNA #2 had a significant decrease in apoptosis as measured by annexin V 
positive/7AAD negative staining at 24 hours (Figure 7A). Indeed, this decrease was 
consistent at all three time points examined. These results suggest that in the PI34 cell 
line, IL-24 is at least partially responsible for the apoptosis caused by ATR inhibition and 
aphidicolin treatment.  
 
Discussion 
IL-24 was first discovered as a tumor suppressor in melanocytes, and since has 
been widely studied as a potential cancer treatment, as overexpression of IL-24 induces 
apoptosis in transformed but not in normal cells157,118. This tumor cell specificity 
theoretically allows for an extremely wide therapeutic window.  
The Brown laboratory previously reported a premature aging phenotype in 
ATRmKO mice and a tissue regenerative defect in ATRΔ/-p53-/- mice. The tissue 
regenerative defect was accompanied by highly damaged cells which produced many 
inflammatory factors, including most prominently, IL-24. Thus, we began investigating 
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IL-24 as a potential p53-independent cell clearance mechanism and driver of 
inflammation in the ATRΔ/-p53-/- mice.  
 In this study, we report that IL-24 is induced specifically by replication-
associated damage in a variety of normal and neoplastic cell types, both human and 
mouse. Interestingly, the induction of IL-24 mRNA peaks within 18 hours of cellular 
damage, and quickly decreases to baseline levels. This suggests that either IL-24 is only 
needed for a brief period of time to perform its function (such as activating other 
pathways), or that IL-24 is being stabilized at the protein level, and continuing to function 
after IL-24 RNA has been degraded. We also show that the IL-24 induction by S-phase 
damage is dependent on p38MAPK, as inhibition of this kinase almost completely 
abrogates IL-24 induction. This result is in accordance with previously published 
papers111, suggesting that the mechanism of p38MAPK regulation of IL-24 occurs at the 
post-transcriptional level.  
Interestingly, we also show that despite being DNA damage-dependent, activation 
of the IL-24 pathway does not require DNA damage proteins ATM, DNA-PK, or ATR. 
In fact, continuous suppression of ATR with aphidicolin treatment substantially increases 
the level of IL-24 induction, as compared to temporary inhibition of ATR. This increase 
with sustained ATR inhibition does not appear to be attributable solely to an increase in 
DNA damage, as there is no obvious increase in γH2AX levels with continuous 
treatment, as compared to a 6 hour pulse.  
Our findings suggest a novel mechanism of IL-24 induction, providing a new 
potential explanation for the efficacy of S-phase damaging agents in cancer therapy, such 
as ATR-Chk1 pathway inhibition. There have already been multiple promising clinical 
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trials utilizing a non-replicating adenoviral vector expressing IL-24 (INGN 241)120,158. 
Currently, there is a Phase 2 trial studying the efficacy of intratumoral injection of INGN 
241. Our results suggest that studies seeking to overexpress IL-24 could benefit from the 
addition of S-phase damaging agents such as ATR inhibitors or camptothecin. It will be 
interesting to further examine the S-phase specificity of IL-24 induction, and to test 
whether IL-24 is responsible for apoptosis due to replication fork collapse in multiple 
tumor types and different drug treatments. 
Additionally, it has been shown that IL-24 can decrease a cell’s ability to protect 
itself from oxidative stress, e.g. by inhibiting the Nrf2-mediated antioxidant response122. 
This report offers an interesting potential connection between IL-19 and IL-24; we 
hypothesize that in some contexts, IL-24 acts as an acute response to DNA damage that 
can amplify ROS levels, which eventually leads to IL-19 upregulation. In this case, IL-
24-facilitated apoptosis would be the primary response to DNA damage associated with 
DNA replication, and IL-19-driven senescence would serve as a backup anti-proliferative 
mechanism. Alternatively, the IL-24 and IL-19 pathways could represent two different 
responses to DNA damage, resulting in apoptosis or senescence, respectively. If the latter 
case is true, it would beg the question of what are the determining factors that decide 
which pathway will be induced or will win out. Further experiments, such as IL-19 
induction in response to DNA damage in IL-24 knockdown cells, will be needed to 
connect or further tease apart these two pathways.   
 
Experimental Procedures 
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Cells. BxPc3 human pancreatic epithelial cells were cultured in DMEM supplemented 
with 10% FBS, 100 units/ml penicillin, 100 ug/ml streptomycin, and 5% fungizone. 
HEK293T cells were obtained from ATCC and cultured as described (CRL-3216). 
WM239A cells were obtained from Eric Witze. PI34 cells were obtained from Benjamin 
Stanger and cultured in DMEM/F12 (Gibco #11320-033) supplemented with 450 g/L D-
glucose, nicotinamide (Sigma #N3376), ITS + premix (BD Biosciences #354352), bovine 
pituitary extract (BD Biosciences #354123), T3 (Sigma #T2877), dexamethasone (Sigma 
#D1756), Nu-serum IV (BD Biosciences 355104), cholera toxin (Sigma #C8052), 100 
units/ml penicillin with 100 ug/ml streptomycin (Invitrogen #15140122), and fungizone 
(Invitrogen #15290018).  
Viruses and Infections. To generate lentiviruses, HEK293T cells were transfected using 
calcium phosphate precipitation of the lentiviral expression vector with pMDL, pVSVG, 
and pRSV-REV. pLKO.1 vectors expressing mouse IL-24 shRNA #1 (sequence 
CCGCAGAGCATTCAAACAGTT) and IL-24 shRNA #2 (sequence 
GTCGCTTTGGTGAAAGCCTTT) were purchased from Open Biosystems 
(TRCN0000065943 and TRCN0000065945, respectively). The control pLKO.1 vector 
expressing a non-targeting has the following sequence: 
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 
(Addgene plasmid #1864, a gift from David Sabatini). 
Quantitative Real-Time PCR. Cells were lysed and RNA was isolated using the 
GeneJet RNA purification kit (Fermentas Life Sciences #K0731). Reverse transcription 
was performed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems Inc. #4368814). Quantitative PCR was then performed using Sybr Green 
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PCR Master Mix (Applied Biosystems Inc. #4309155). Primer sets are as follows 
(human=H, mouse=M): 
Gene 
(H/M) 
Forward Primer Reverse Primer 
IL-1β (H) GGCCCTAAACAGATGAAGTGCT TGCCGCCATCCAGAGG 
IL-6 (H) CCAGGAGCCCAGCTATGAAC CCCAGGGAGAAGGCAACTG 
IL-8 (H) TTGGCAGCCTTCCTGATTTC TCTTTAGCACTCCTTGGCAAAAC 
IL-19 (H) TACGTGGACAGGGTGTTCAA ATGACTCTGGTGGCATTGGT 
IL-20 (H) TTGCCTTCAGCCTTCTCTCT CATCTTTGGCTTGCACACTG 
IL-24 (H) GCTTTCGCCAATTTAACACC GCTCCAGAGAAGCAGGGTAA 
GAPDH (H) CGAATTTGGCTACAGCAACAGG GTACATGACAAGGTGCGGCTC 
IL-1β (M) TGGACCTTCCAGGATGAGGACA GTTCATCTCGGAGCCTGTAGTG 
IL-6 (M) TGGAGTCACAGAAGGAGTGGCTAAG TCTGACCACAGTGAGGAATGTCCAC 
IL-19 (M) ATCCTGTCCCTGGAGAACCT CAAGGCTTCTCTCCTGATGG 
IL-24B (M) CACTCTGGCCAACAACTTCA GCTTTCACCAAAGCGACTTC 
IL-24D (M) TGACATCACAAGCATCCGG GGCAAGGTAACAGCTCTCAG 
Actin (M) ACCTTCTACAATGAGCTGCG CTGGATGGCTACGTACATGG 
 
Western Blotting. Following direct addition of Laemmeli sample buffer, whole cell 
lysates were vortexed briefly, boiled at 98°C for 5 minutes, loaded on 4-20% gradient 
SDS-polyacrylamide gels (Thermo Scientific #0025244), and separated by 
electrophoresis. Proteins were then transferred to PVDF membranes, blocked in 5% milk 
in TBST for 1 hour at RT, bound to primary antibodies in blocking buffer (4°C 
overnight), washed, and then detected with horseradish peroxidase-conjugated secondary 
antibodies and chemiluminescence (Thermo Scientific #34080).  
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Antibodies. Anti-phospho-H2AX (Ser139) was purchased from Millipore (Cat #05-636). 
Anti-phospho-Chk1 (Ser345) was purchased from Cell Signaling (Cat #2348). Anti-actin 
was purchased from Santa Cruz (Cat #sc-1616). Annexin V-APC was purchased from 
BD Pharmingen (Cat #550475). Anti-phospho-p38MAPK(Thr180/Tyr182) and total 
p38MAPK were purchased from Cell Signaling (Cat #9216 and #9212, respectively).  
Chemicals and Inhibitors. ATM inhibitor (KU55933), DNA-PK inhibitor II (NU7026), 
and ATR-AZ inhibitor (CAS Registry Number: 1233339-36-0, Foote, et al., 2013) were 
purchased from Calbiochem (Cat #118500 and #260961) or synthesized (Foote, et al., 
2013). ATR45 was purchased from OSU (Cat #ATR45). p38MAPK (SB203580) was 
purchased from Selleckchem (Cat #S1076). 7AAD staining solution was purchased from 
BD Pharmingen (Cat # 559925). Caspase-1 inhibitor (InSolution Q-VD-OPh) was 
purchased from EMD Millipore (Cat #551476). Camptothecin was purchased from 
Sigma Aldrich (Cat #C9911).  
 
Apoptosis Assay. Cells were pelleted and resuspended in annexin V binding buffer (0.1 
mM Hepes, 1.4 M NaCl, 25 mM CaCl2). Cells were then stained with Annexin V 
conjugated to APC and 7AAD, and subjected to flow cytometry on a FACSCalibur (BD 
Biosciences).  
 
Figure Legends 
Figure 3.1. Fork stalling caused by ATR inhibition plus DNA polymerase inhibition 
cause an induction of IL-24. (A) Schematic of experimental design. (B-D) BxPc3 cells 
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were treated with 5 uM aphidicolin (B), 5 uM ATR45 (C), or both 5 uM aphidicolin and 
5 uM ATR45 (D) for 6 hours, and collected from 1 to 62 hours later and analyzed by 
qRT-PCR. Fold change was normalized to GAPDH and compared to DMSO controls. (E) 
BxPc3 cells were treated with 2.5 uM ATR-AZ and 5 uM aphidicolin for 6 hours, 
collected 3-72 hours later, and analyzed by qRT-PCR as in A-C.  
Figure 3.2. IL-24 induction occurs in multiple cell types. (A) WM239A cells were 
treated with 2.5 uM ATR-AZ and 5 uM aphidicolin for or CPT 6 hours, washed to 
remove drugs, and incubated for 18 hours before collection and analysis for IL-24 
expression by qRT-PCR. Fold change was normalized to GAPDH and compared to 
DMSO control. (B) PI34 cells were treated with 2 uM ATR45 and 5 uM aphidicolin for 6 
hours, washed to remove drugs, and collected 4-82 hours later. Cells were then lysed and 
analyzed for expression of various cytokines by qRT-PCR. Fold change was compared to 
cells at the 0 hour time point and normalized to actin levels.  
Figure 3.3. IL-24 induction is independent of cell death. BxPc3 cells were treated with 
2.5 uM ATR-AZ and 5 uM aphidicolin for 6 hours in the presence of 20 uM QVD, 
washed to remove ATR-AZ and aphidicolin, QVD was re-added to the media, and cells 
were incubated for an addition 18 or 24 hours before collection and analysis for IL-24 
induction by qRT-PCR. Fold change was normalized to GAPDH and compared to 
DMSO controls. 
Figure 3.4. Camptothecin induces a significant increase in IL-24 levels. (A) BxPc3 cells 
have similar levels of DNA damage when treated with 5 uM ATR45 plus 5 uM 
aphidicolin for 6 hours or 2.5 uM camptothecin for 6 hours. (B) Time course of 
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interleukin mRNA induction in BxPc3 cells treated with 2.5 uM camptothecin for 6 
hours. Fold change was normalized to GAPDH and compared to the 0 hour control.  
Figure 3.5. Etoposide treatment does not induce a significant IL-24 response. (A) Level 
of DNA damage in BxPc3 caused by 6 hour treatment with 2.5 uM CPT is comparable to 
DNA damage caused by 1 hour treatment of 20 uM etoposide. (B) Interleukin levels in 
BxPc3 cells treated with 20 uM etoposide for 1 hour and collected 4-64 hours later. Fold 
change was normalized to GAPDH and compared to the 0 hour control.  
Figure 3.6. IR does not induce an IL-24 mRNA peak at 18 hours. BxPc3 cells were 
irradiated with 10 Gy IR and collected 4-70 hours later and analyzed for interleukin 
induction by qRT-PCR. Fold change was compared to non-irradiated control plates and 
normalized to GAPDH. 
Figure 3.7. IL-24 induction is independent of ATM and DNA-PK. BxPc3 cells were 
treated with different combinations of ATR-AZ and aphidicolin, ATM inhibitor, and 
DNA-PK inhibitor, and collected 18 hours after ATR-AZ and aphidicolin (or DMSO) 
treatment. ATM inhibitor and DNA-PK inhibitor were kept in the media of the relevant 
samples throughout the entire experiment. Fold change in mRNA was compared to 
DMSO control and normalized to GAPDH. 
Figure 3.8. ATR inhibition intensifies IL-24 induction. (A) Schematic of the 
experimental design. (B) BxPc3 cells treated with 5 uM aphidicolin for 6 hours, with 
continuous ATR inhibition or 6 hour ATR inhibition (with 2.5 uM ATR-AZ). Cells were 
collected 18 hours after aphidicolin wash-out and analyzed for IL-24 expression by qRT-
PCR. Fold change was compared to DMSO control and normalized to GAPDH levels. 
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Figure 3.9. ATR inhibitor-driven increased IL-24 likely not due to increased level of 
DNA damage. Western blot of γH2AX and phospho-Chk1 as surrogates for DNA 
damage and ATR activation, respectively, in response to different inhibitors. BxPc3 cells 
were treated with different combinations of CPT, ATR-AZ, Aph, and DNA-PK inhibitor 
for 6 hours or continuously, as described.  
Figure 3.10. p38MAPK activation required for IL-24 induction by ATR inhibition and 
aphidicolin treatment. (A) Western blot showing p38MAPK activation and inhibition in 
BxPc3 cells treated with ATR-AZ and aphidicolin for 6 hours and recovered for 18 
hours. (B) IL-24 mRNA levels in BxPc3 cells treated with ATR inhibitor and aphidicolin 
for 6 hours in the presence or absence of p38MAPK inhibitor, collected 6 or 18 hours 
after ATR inhibitor and aphidicolin washout, analyzed by qRT-PCR. Fold change 
compared to DMSO control, normalized to GAPDH.  
Figure 3.11. IL-24 knockdown decreases apoptosis due to ATR inhibition and 
aphidicolin treatment. (A) FACS plots showing annexin V and 7AAD staining in PI34 
cells expressing control or IL-24 shRNAs, treated with ATR45 and aphidicolin, 24 hours 
after drug washout. (B) Graph of % apoptosis of same cells in (A) determined by flow 
cytometry analysis of annexin V and 7AAD staining 0-24 hours after ATR45 and 
aphidicolin treatment.  
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Figure 3.1 
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Figure 3.2 
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Figure 3.3 
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Figure 3.4 
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Figure 3.5 
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Figure 3.6 
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Figure 3.7 
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Figure 3.8 
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Figure 3.9 
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Figure 3.10 
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Figure 3.11 
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IL-10 family members are involved in DNA damage and stress responses 
The impact of senescence and the SASP on cancer and aging has been clearly 
established. The non-cell autonomous and cell autonomous factors involved in 
responding to DNA damage and other stresses, as well as regulating that response, 
however, still require further characterization. Additionally, the importance of ROS in 
cancer and aging, specifically the connection between ROS and senescence-inducing 
stimuli, requires clarification, as does JNK’s involvement. The more these regulatory 
pathways are understood, the more likely they can be used to guide novel therapeutic 
treatments.  
We found that IL-19 is a novel SASP factor that regulates IL-1α and other SASP 
factors including IL-6 and IL-8 in response to IR. Additionally, we found that IL-19 is 
regulated by ROS and oxidative stress via the JNK pathway, rather than the classical 
SASP regulatory pathway of DDR proteins such as ATM. Thus, we show that ROS are 
linked to SASP via IL-19, and that IL-19 might also be part of the connection between 
ROS and senescence, since both ROS and IL-19 increase in passage-induced and 
oncogene-induced senescence.  
IL-24 already has an established role in cancer prevention and cancer treatment. 
The stimuli that lead to IL-24 upregulation, however, need to be investigated further. We 
show that IL-24 is a stress-responsive gene that is most impressively upregulated with S-
phase specific types of DNA damage. This stress-induced regulation is in agreement with 
a study that showed IL-24 upregulation in response to bacterial intoxication159, a stress 
that also causes a DNA damage response. In fact, this group proposed the idea that IL-24 
might be part of a general cellular response to genotoxic stress159.  
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We further show that this S-phase damage-initiated IL-24 induction is dependent 
on p38MAPK signaling, but not ATM, ATR, or DNA-PK. Additionally, sustained ATR 
inhibition greatly intensifies the IL-24 response, without a concomitant increase in DSBs, 
suggesting that ATR may suppress IL-24 in non-stressful conditions through more than 
ATR’s traditional role of preventing DSB formation from stalled replication forks. All of 
these results suggest that IL-24 may be responsible for the therapeutic response seen with 
ATR-CHK1 pathway inhibitors in cancer treatment. If this is true, then the level of IL-24 
induction with ATR inhibitors could be used to determine whether tumors will be 
responsive to ATR inhibitor therapy. Further study of ATR’s role in IL-24 regulation will 
have to be performed in order to determine whether replication fork-specific proteins are 
involved in preventing IL-24 induction.  
Our data suggest that IL-19 may regulate senescence, while IL-24, by contrast, 
regulates apoptosis. The time frames of their regulation are drastically different; while 
IL-24 mRNA reaches a maximum within 24 hours after stress and quickly returns to 
baseline, IL-19 mRNA increases slowly after stress, reaching a maximum 3-4 days later. 
The differential regulation of these two genes may represent a cellular “decision” 
between undergoing cell death versus undergoing senescence. For example, if IL-24 is 
induced after damage, then the cell may undergo apoptosis before it has a chance to 
upregulate IL-19. Alternatively, IL-24 expression could prevent upregulation of IL-19 
more directly. Further delineation of the differences between IL-19 and IL-24, as well as 
whether any other IL-10 family members are involved in similar processes, will be 
needed in the future. 
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Therapeutic Implications and Opportunities  
The importance of teasing apart these regulatory pathways is especially true as the 
beneficial and detrimental effects of senescence continue to be discovered, so that these 
two categories of effects can be separated as much as possible. In other words, the more 
that is known about the way each component of the SASP is regulated, the more likely 
we will be able to ensure that their positive attributes are maintained while their negative 
effects are modified or minimized. For example, finding a way to decrease production of 
growth- and EMT-stimulatory factors without decreasing production of factors that help 
enforce senescence, would allow for senescent cells to stay in their environment without 
promoting tumorigenesis or metastasis in a paracrine manner. In some cases, however, 
such as the radiation bystander effect or paracrine senescence, paracrine signaling 
through the SASP is beneficial for successful cancer treatment. Thus, the group of 
secreted factors would ideally be modified in a context-dependent manner, similar to the 
way in which it is becoming increasingly commonplace in cancer treatments to determine 
which chemotherapeutics to use based on extensive genotyping data. In other words, in 
order to be effective, SASP-based treatments for aging and cancer will need to enter the 
realm of personalized medicine. 
Another difficulty in adjusting these effects for therapeutic purposes lies in the 
delivery of any modifying treatments to a specific location, as would be needed at least in 
the context of cancer treatment, if not aging as well. For example, if recombinant factors 
or receptor antagonists were utilized to enhance or dampen certain SASP components, 
they would need to be targeted specifically to the tumor or at least the organ of interest. 
Ideally, these treatments would contain some version of a homing device to target the 
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drugs directly to senescent cells. Before this type of homing device can be 
conceptualized, however, more research into targetable unique characteristics of 
senescent cells, such as receptors that are only expressed on the surface of senescent 
cells, will need to be performed. 
In terms of therapeutic opportunities, blocking IL-19 signaling during cancer 
treatment (such as breast cancer, or cancers treated with DSB-inducing agents including 
radiation) could increase the number of cells that undergo apoptosis instead of 
senescence, and/or could decrease the negative paracrine effects normally seen from 
SASP factor signaling after treatment. Potential drawbacks would be if the cells that 
bypass senescence due to a lack of IL-19 signaling do not undergo apoptosis and instead 
continue replicating, or if the bystander-induced cell killing phenomenon were blunted 
due to a lack of SASP factor expression.  
Although our studies only encompass a few different cell lines, there are some 
studies that suggest that IL-19 may regulate IL-6 in other cell types in vivo. For example, 
an IL-6 knockout mouse model (IL-6-/-) has been reported to have a more severe response 
to DSS treatment than wild-type mice160. This is similar to the sensitivity to DSS-induced 
colitis seen in IL-19 knockout mice98.  Also, like IL-19, IL-6 has an important role in 
various inflammatory disorders, including rheumatoid arthritis161 and inflammatory 
bowel disease162. These similar phenotypes between IL-19- and IL-6-knockout mice, 
accompanied with various similarities seen in other contexts and in our results as reported 
above, suggest that IL-19 may have a role in various inflammatory contexts via IL-6.  
If IL-19 indeed regulates IL-1 and/or IL-6 in a variety of contexts, this will 
significantly broaden IL-19’s importance in a plethora of diseases and physiological 
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processes. IL-6 has been broadly studied, and IL-6 modulation is already a widely 
applicable drug treatment. IL-6 is targeted by the monoclonal antibody siltuximab, and 
the IL-6 receptor is targeted by the monoclonal antibody tocilizumab. Tocilizumab has 
already been approved for use in rheumatoid arthritis and Castleman’s disease, among 
others. There are several additional agents currently in clinical trials and in development. 
Thus, IL-19 may be a novel target in some or many processes that involve dysregulation 
of IL-6, or where IL-6 signaling modulation would be beneficial.  
This additional target may prove especially useful in cases where IL-6 targeting is 
especially difficult; targeting IL-19 instead of, or in addition to, IL-6, has the potential to 
be extremely effective. First of all, IL-19 is upstream of IL-6, so targeting IL-19 may 
have a greater impact on IL-6 down-regulation than specifically targeting IL-6. Instead of 
needing a high concentration of antibodies to block IL-6 protein or IL-6 signaling, IL-6 
could be decreased at the transcriptional level. Additionally, in cases where IL-6 
induction is dependent on IL-1, IL-19 knockdown would prevent IL-1 induction and 
consequent IL-6 induction. In other words, IL-19 affords the opportunity to regulate IL-6 
at a much earlier stage. 
One example in which inhibiting IL-6 induction by regulating IL-19 might be 
especially important is in the tumor microenvironment. IL-6 has been shown to cause as 
well as maintain a pro-tumorigenic environment, partly by supporting angiogenesis and 
promoting tumor evasion of immune surveillance163. In these cases, blocking IL-19 in 
order to diminish the IL-6 pathway would be beneficial. Because the pathways we 
described that lead to IL-19 induction, namely ROS and JNK, are important in many 
contexts, the ideal drug would be able to target ROS and/or JNK signaling in an IL-19-
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dependent manner. For example, an ROS scavenger (or activator of the antioxidant 
pathway) or JNK inhibitor could be linked to another protein that maintains it in an 
inactive state until it is cleaved by a short-lived enzyme that is expressed in an IL-19-
inducible manner. Thus, the pathway that activates IL-19 would only be inhibited while 
IL-19 is expressed.  
There are other situations, however, where IL-6 induction or potentiation via IL-
19 stimulation would be advantageous. For example, IL-6 can increase activation of anti-
tumor T-cells as well as their recruitment to tumor sites163. In these cases, the regulatory 
pathways that induce IL-19 expression could be stimulated in order to cause production 
of IL-19 and downstream IL-6. ROS-generators or JNK activators are potential effectors 
in these cases. Once the transcription factors that regulate IL-19 induction or the RNA-
binding proteins that regulate RNA stability of IL-19 mRNA downstream of ROS or JNK 
activation are delineated, they will also be potential targets. 
Since we also demonstrate a role for IL-19 in IL-1 and IL-8 regulation, we also 
open up the possibility that IL-19 is involved in a multitude of other IL-1- and IL-8-
regulated processes. For example, IL-19 may regulate IL-8 in the context of inducing 
neutrophil chemotaxis or promoting angiogenesis (by targeting endothelial cells), as well 
as enhancing proliferation and survival of cancer cells in an autocrine manner164. 
Importantly, drug- and stress-induced IL-8 signaling is able to increase resistance to 
chemotherapy in cancer cells164. Thus, being able to target IL-8 through IL-19 in the 
context of cancer and chemotherapeutic treatment could significantly improve treatment 
outcomes.     
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Our studies also posit a causative link between oxidative stress and aging, through 
the regulation of IL-19. Determining the type, amount, or context of ROS necessary to 
cause IL-19 induction could give further clues as to why ROS can act as non-aging-
related signaling molecules in certain contexts, while in others, they are necessary or 
even sufficient for causing aging phenotypes.  
 
Future Directions  
For future directions regarding IL-19 studies, it would be interesting to perform 
an RNA sequencing experiment to see if there is a subset of SASP factors that are 
independent of IL-19, or if IL-19 regulates additional SASP factors. It is also possible 
that IL-19 regulates other pathways in addition to the SASP factors, which might result in 
discovery of new factors that are important in senescence and aging. Additionally, it will 
be important to define IL-19’s role in passage-induced and oncogene-induced 
senescence, as well as passage-induced and oncogene-induced SASP factor induction.  
It would be interesting to test the response to different types of stress, including 
tissue regeneration and stem cell maintenance, as well as observe the natural aging 
process in IL-19 knockout mice. Testing whether interference with IL-19 signaling or 
induction in mouse models of premature aging have significant effects on the aging 
phenotypes would also be informative. This could be done by crossing genetic mouse 
models of premature aging onto an IL-19-/- background or by using drugs such as small 
molecule inhibitors to prevent IL-19 signaling. However, the most useful mouse for these 
studies would be one with an inducible deletion of IL-19, which to our knowledge has yet 
to be generated.   
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One important future direction for the IL-24 studies is further dissection of the IL-
24 regulatory pathway. If IL-24 induction is indeed S-phase-specific, what determines 
this specificity? It is possible that IL-24 induction requires signaling from proteins that 
are activated specifically by stalled replication forks, besides ATR. In fact, based on the 
significant increase in IL-24 expression in the absence of ATR, IL-24 could be regulated 
by a pathway that is normally suppressed by ATR. Another possibility is that IL-24 
induction requires a protein or pathway that is only active during S-phase. These 
possibilities can be tested using a candidate approach, e.g. by examining pathways that 
are regulated by ATR or known to be specifically upregulated in S-phase.  
Additionally, studying IL-24 induction in an in vivo tumor model would be 
informative as to IL-24’s role in cancer progression and treatment efficacy. For example, 
comparing the response of tumors with normal IL-24 expression to tumors with IL-24 
knockdown via shRNAs to different drugs would determine the importance of IL-24 in 
the response to different drug treatments. Similarly, IL-24 could be used as a biomarker 
to determine efficacy of different drugs for multiple tumor types in patients. If IL-24 is a 
successful biomarker, IL-24 status could guide treatments towards S-phase specific 
damage-inducers, versus agents that cause non-specific genotoxic stress, thereby treating 
tumors more selectively and minimizing side effects.    
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